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DETERMINATION OF NOVEL METABOLITES OF THERAPEUTIC 
AGENTS USED IN THE TREATMENT OF CASTRATION-RESISTANT 
PROSTATE CANCER 
MOHAMMAD ALYAMANI 
ABSTRACT 
Despite an array of improved treatment options over the past decade, prostate 
cancer remains the second leading cause of cancer mortality for men in the United States. 
Abiraterone and galeterone are oral steroidal compounds that are used to treat metastatic 
castration-resistant prostate cancer (CRPC). Abiraterone blocks 17α-hydroxylase/17,20-
lyase (CYP17A1), an enzyme required for androgen synthesis. Galeterone inhibits 
CYP17A1, blocks the androgen receptor (AR), and decreases AR protein levels. Both 
drugs share the same structure with endogenous androgens such as 
dehydroepiandrosterone, which are substrates for the enzyme, 3β-hydroxysteroid 
dehydrogenase (3βHSD). Metabolites of 3βHSD undergo further metabolism to produce 
the AR ligand, testosterone and dihydrotestosterone. 
Overall this project aimed to investigate the steroidogenic metabolism of 
abiraterone and galeterone and evaluate the metabolites’ role in prostate cancer. The 
background on prostate cancer, steroid biosynthesis, and treatment options is described in 
Chapter I. Chapter II describes the development and validation of a liquid chromatography 
mass spectrometry method LC-MS/MS to determine abiraterone metabolites. My method 
distinguished between all the diastereoisomers with conventional chromatographic 
  vii 
conditions. In chapter III and IV my validated LC-MS/MS method was utilized to study 
the metabolism of abiraterone in vitro using prostate cancer cell lines and in vivo using 
mice. It also helped in determining abiraterone metabolites in a pharmacokinetic trial in 
healthy human subjects and in prostate cancer patients enrolled in several clinical trials. 
The trials aimed to evaluate the standard dose of abiraterone acetate, combining abiraterone 
acetate with androgen deprivation therapy (ADT), adding dutasteride (an SRD5A 
inhibitor), or increasing the frequency of the standard dose of abiraterone acetate. In 
chapter V, galeterone metabolism was studied in vitro and in vivo and the metabolites’ 
activities were evaluated for their roles in prostate cancer. Chapter VI discusses the overall 
conclusions and future directions.   
This project identified a new subset of abiraterone and galeterone metabolites that 
are generated by steroidogenic enzyme conversion.  These metabolites had opposing 
effects on prostate cancer. These findings suggest a common pathway for steroidal drugs 
with a Δ5, 3β-hydroxyl structure. This project also provides new strategies in prostate 
cancer treatment that will make the current treatment options more beneficial.   
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CHAPTER I 
PROSTATE CANCER: AN OVERVIEW 
 
 
 
1.1. Background 
“A very rare disease” is how J. Adams, the surgeon at The London Hospital, 
described the first case of prostate cancer, which he discovered by histological examination 
in 18531. After more than 160 years, prostate cancer is the most frequently diagnosed 
cancer and the third leading cause of cancer death in men in the United States. One out of 
seven American men will be diagnosed with prostate cancer during their lifetime. In 2017, 
it is estimated that 160,000 American men will be diagnosed with prostate cancer and 
26,000 will lose their lives to the disease2. 
The prostate gland is part of the male reproductive system. It is a walnut size and 
shaped organ. It sits below the bladder just in front of the rectum and surrounds part of 
the urethra. The role of the prostate is to help make the semen. Even though researchers do 
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not know exactly what causes prostate cancer, several factors can be linked to it: age, 
ethnicity, heredity, and geographic region3.  The older the man is, the higher the possibility 
of being diagnosed with prostate cancer. According to recent statistics from the Prostate 
Cancer Foundation, 65% of prostate cancer patients are older than 65 years old. Compared 
with Caucasian and Asian men, African American men are more likely to develop prostate 
cancer and are more likely to die from the disease. The chance of being diagnosed with 
prostate cancer will double if a man has a father or brother who developed prostate cancer. 
Those who live in the northern part of the United States are at higher risk to develop and 
die from the disease. Although why this pattern exists is unclear, it may be that low 
exposure to sun light and vitamin D deficiency can increase the disease rates4. Other factors 
that can be linked to prostate cancer include diet, obesity, and smoking5. 
1.2. The Androgen Receptor 
Prostate cancer is a hormone-dependent malignancy; tumor progression depends 
on androgen receptor AR presence and function6,7. AR belongs to the steroid hormone 
group of nuclear receptors, along with the estrogen receptor (ER), glucocorticoid receptor 
(GR), progesterone receptor (PR) and mineralocorticoid receptor (MR)8. Testosterone (T) 
and its more potent metabolite, 5α-dihydrotestosterone (DHT), are the ligands for 
activating the AR. Therefore, these two steroids are the endogenous ligands fueling the 
growth of malignant prostate cells. DHT is 10 times more potent than T in activating the 
AR9. AR protein is encoded by the AR gene located on the X chromosome at Xq11-12 and 
spans ~180 kb of DNA containing 8 canonical exons. The AR contains four domains: (I) 
the amino terminal activation domain (NTD); (II) the DNA-binding domain (DBD); (III) 
the hinge region (HR) and (IV), the carboxyl ligand-binding domain (LBD). NTD, which 
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is encoded by exon 1, is the transcriptional regulatory region of the AR containing 
activation function-1 (AF-1). The DBD, composed of two zinc finger motifs, is encoded 
by exons 2 and 3, respectively. The hinge region is encoded by exon 4. The LBD is encoded 
by exons 5–8 and contains activation function-2 (AF-2) that allows the recruitment of co-
activators and co-repressors (Fig 1). The transcriptional activity of the AR requires AF-1 
in its NTD with negligible activity being attributed to AF-2 region in the LBD10,11. 
When androgens such as DHT diffuse through the plasma membrane of the cell and 
bind to the LBD of AR, they will initiate cellular events involving conformational changes, 
receptor stabilization, and nuclear translocation. It will also result in binding of AR dimer 
to androgen response elements (AREs) located in the promoter and enhancer sequences of 
target genes. AR binds target AREs via its DBD; a portion of the DBD together with the 
hinge region encode for a nuclear localization signal (NLS)12,13 (Fig. 2).  
1.3. Regulation of Testosterone Synthesis by the Endocrine Axis 
The major source of circulating testosterone are the testes; however the adrenal 
gland can also produce T by regulating androgen biosynthesis. The endocrine axis 
contributes to the growth of prostate cancer by regulating T synthesis in these two sources: 
(i) the hypothalamus-pituitary-gonadal axis (HPG axis) and (ii) the hypothalamus-
pituitary-adrenal axis (HPA axis)14,15. In the hypothalamus, gonadotropin-releasing 
hormone (GnRH), also known as luteinizing hormone (LH)-releasing hormone (LHRH), 
is produced and travels to the anterior pituitary and interacts with LHRH receptors (LHRH-
Rs). Due to this interaction, LH will be released into the blood stream. In the testes, the 
released LH binds to its receptors (LH-R), inducing T production. The hypothalamus also 
produces corticotropin-releasing hormone (CRH). CRH stimulates the secretion of 
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adrenocorticotropic hormone (ACTH) from the pituitary into the blood stream where it 
interacts with the adrenal cortex portion of the adrenal gland and stimulates the synthesis 
of adrenal androgens, including T (Fig 3). T synthesized and released from both sites enters 
the prostate cells, where it is converted to 5α-dihydrotestosterone (DHT) by the enzyme 
5α-reductase SRD5A. DHT binds tightly to AR, enters the cytoplasm, and the complex 
translocates to the nucleus, where it activates transcription of genes that regulate cell 
growth and survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 
 
 
 
 
 
 
Figure 1. Genomic organization of the AR gene. 
(Source: Quigley, C. A,1995)11 
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Figure 2. Ligand-dependent activation of the AR. 
CBP (CREB-binding protein); hsp (heat shock protein); SRC-1 (steroid receptor 
coactivator 1) (Source: Meehan, K. L; 2003)12. 
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Figure 3. The regulation of androgen synthesis by the HPA and HPG axes. 
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1.4. Steroid Biosynthesis (Steroidogenesis) 
Cholesterol is the precursor for steroid biosynthesis16,17. This 27-carbon compound 
can be oxidized to 21-carbon steroids (progestins, glucocorticoids, and mineralocorticoids) 
that then can form 19-carbon androgens. As discussed in section 1.3, the two primary 
sources of androgens are the adrenal cortex and the Leydig cells. Enzymes involved in 
steroidogenesis are either part of the cytochrome P450 (CYP) system, which is a group of 
oxidative enzymes that contain a single heme group and almost 500 amino acids18, or 
hydroxysteroid dehydrogenases (HSDs), which contain heme groups and require 
nicotinamide adenine dinucleotide as a cofactor for their activity. Structurally, HSDs 
belong to two groups of enzymes: the short-chain dehydrogenase reductase (SDR) family 
or the aldo-keto reductase (AKR) family19. CYP reactions are irreversible, meaning that 
the accumulation of product will not drive flux to its precursor. On the other hand, some 
HSD reactions are reversible. The first step of steroidogenesis is catalyzed by CYP11A1, 
which results in side chain cleavage of cholesterol to pregnenolone (Fig. 4).  CYP17A1 
(17α-hydroxylase and 17,20 lyase) converts pregnenolone to 17 hydroxy-pregnenolone 
and then to dehydroepiandrosterone (DHEA). 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 
isomerase (3βHSD) irreversibly converts 3β-OH, Δ5 steroids to 3-keto, Δ4 steroids. Two 
isoforms of 3βHSD are present in human, with 3βHSD1 being the isoenzyme dominantly 
expressed in peripheral tissue. This enzyme converts pregnenolone to progesterone, 17-
hydroxypregnenolone to 17-hydroxyprogesterone, DHEA to androstendione (AD), and Δ5-
Androstenediol (A5diol) to T.  
The Sharifi lab reported that in CRPC a mutation in the gene coding for 3βHSD 
results in increased DHT levels20. Steroid-5α-reductase (SRD5A) converts 3-keto, Δ4 
  9 
steroids to 5α-reduced steroids. Two isoforms of SRD5A are present in human. This 
enzyme converts AD to 5α-androstanedione (5α-dione) and T to DHT. It has been reported 
that in CRPC, conversion of AD to T is less favored and DHT synthesis requires conversion 
of AD to 5α-dione, where AD is the favored 5α-reductase substrate21. 17β-hydroxysteroid 
dehydrogenase (17βHSD) reversibly converts 17 keto-androgens to 17 hydroxy-
androgens. Fourteen 17βHSD isoenzymes are present in humans; some have a preference 
for the reductive reaction (17-keto to 17-hydroxyl) and some prefer the reverse reaction. In 
males, 17βHSD3 is the isoenzyme responsible for T synthesis in the testes. However, in 
CRPC, 17βHSD5, also known as the aldo-keto reductase 1C3, another reductive enzyme 
and converts AD to T, is up-regulated22,23. 3α-hydroxysteroid dehydrogenase (3αHSD) is 
also an aldo-keto reductase; it has four isoenzymes and although it is required for 
converting active steroids to inactive steroids, it can be involved in the backdoor DHT 
synthesis pathway24,25.  
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Figure 4. DHT synthesis pathways. 
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1.5. The Development of Castration-Resistant Prostate Cancer 
Prostate cancer develops in stages. In its early stages the tumor is found in the 
prostate only. In this stage, prostate cancer is microscopic; it cannot be felt on a digital 
rectal exam (DRE), and it is not seen on imaging of the prostate. The tumor then spreads 
but still inside the prostate and does not extend beyond it. After that the tumor will spread 
outside the prostate but only barely, and may involve the nearby tissues like the seminal 
vesicles. In its latest stages the tumor will spread (metastasize) outside the prostate to other 
tissues (lymph nodes, the bones, liver, or lungs). The treatment option will depend on the 
stage: active surveillance, radical prostatectomy, or radiation therapy (external beam or 
brachytherapy) are the options for localized disease. In the advanced stages, chemotherapy 
and hormonal therapy are the options. Hormonal therapy is the gold standard for treating 
patients with prostate cancer26-28. The discoveries of Charles Huggins concerning hormonal 
therapy to treat prostate cancer led him to win Nobel Prize in 1966. In his early research, 
Huggins found that castration or estrogen administration shrinks the tissue29,30. His 
discoveries led to what is known now as androgen deprivation therapy, or ADT, which can 
be achieved either by surgical castration (orchiectomy) or medical castration using a GnRH 
agonist or antagonist. ADT will lower serum T levels and it initially works in many cases; 
however, the tissue can still find its fuel which leads it to resist this treatment and the tumor 
will develop to the castration-resistant prostate cancer CRPC stage22,31,32. Second-
generation hormone therapies such as abiraterone acetate and enzalutamide are treatment 
options at the CRPC stage33-36 (Fig 5A&B).  
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Figure 5. Treatment options for prostate cancer 
(Source; Gomez, L. 2015)28 
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1.6. Abiraterone  
Abiraterone [abi; 17-(3-pyridyl)-androsta-5,16-dien-3β-ol] is a 17-heteroazole 
steroidal compound and a potent inhibitor of steroid 17α-hydroxylase/17,20-lyase 
(CYP17A1), an enzyme required for androgen synthesis37. Abiraterone’s structure makes 
it a potent CYP17A1 inhibitor, and the double bond at C16 is necessary for functionally 
irreversible inhibition of the enzyme38-40. Abiraterone is administered as the prodrug, 
abiraterone acetate (AA), for the treatment of CRPC and prolongs survival for these 
patients34,41,42. In 2011, the United States Food and Drug Administration (FDA) approved 
AA in the post-chemotherapy setting, and in December 2012 it approved the use of AA for 
patients with chemotherapy-naïve CRPC43. Prednisone is administered with AA to block 
mineralocorticoid excess that occurs with the simultaneous inhibition of cortisol 
synthesis27,44. The major recognized metabolites of abiraterone result from hepatic 
CYP3A4 and SULT2A1 processing, forming the N-oxide of abiraterone and abiraterone 
sulfate45, respectively.  Neither of these modifications affect the Δ5, 3β-hydroxyl-structure 
of the steroid backbone.  
1.7. Galeterone 
Galeterone (Gal), 17-(1H-benzimidazol-1-yl) androsta-5,16-dien-3β-ol, is a 
steroidal 17-azole compound that inhibits CYP17A146-49, directly competes with androgens 
to bind and antagonize AR50, promotes AR protein degradation, and has clinical activity as 
reported in a phase I/II clinical trial51-55. Galeterone’s structure enables interaction with the 
steroid binding site of CYP17 in addition to coordination with the enzyme’s heme iron, 
resulting in a highly specific and tightly binding inhibitor. The x-ray crystal structure of 
CYP17A1 binding to abiraterone or galeterone shows that they bind to heme iron56. 
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Galeterone shares its Δ5, 3β-hydroxyl structure with abiraterone.  The two drugs are 
distinguished by their C17 moieties – the benzamidazole ring of galeterone and the 3-
pyridyl structure of abiraterone.  These differences may explain why galeterone has been 
reported to have more direct effects on AR.  
1.8. Hypothesis  
Δ5, 3β-hydroxyl steroids are substrates of the enzyme 3βHSD, which irreversibly 
converts them to 3-keto, Δ4 steroids. An example of this is the conversion of DHEA to AD 
and A5diol to T. The next step is then 5α reduction of 3-keto, Δ4 steroids by SRD5A to 
form 3-keto-5α reduced steroids, as present in T conversion to DHT. AKR1C2 will then 
reduce the 3-keto-5α steroids to the 3α-OH-5α steroids. This last step is one mechanism of 
DHT elimination. DHT is converted to 5α-androstan-3α,17β-diol (3α-diol) (Fig. 4).  
Both abiraterone and galeterone are Δ5, 3β-hydroxyl steroids.  Therefore, they can 
be possible substrates of 3βHSD and converted to their 3-keto, Δ4 structures, which may 
follow the downstream mechanism and be converted to the 5α-reduced form. The main 
aim of this project is to study abiraterone and galeterone metabolism by steroidogenic 
enzymes and study the activity of the resultant metabolites. The metabolism was studied 
in vitro using prostate cancer cell lines and in vivo using NSG mice.  I hypothesized that 
the enzymes present in prostate cancer cell lines and in mice will convert abiraterone 
and galeterone to their steroidogenic enzyme metabolites and this conversion is 
irreversible. Galeterone metabolite activity was studied in vitro and in vivo. I 
hypothesized that galeterone metabolites will show activity toward the AR signaling 
pathway in prostate cancer cell lines, and in mouse models, the metabolites will have 
activity directed against tumors in mouse xenograft models. Abiraterone metabolism 
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was investigated in patients with CRPC who are treated with abiraterone acetate in clinical 
trials. I hypothesized that inhibiting steroidogenic enzymes or increasing the 
frequency of abiraterone dose will affect abiraterone metabolite levels in CRPC 
patients which may correlate with clinical outcomes.   
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CHAPTER II 
DEVELOPMENT AND VALIDATION OF A NOVEL LC-MS/MS METHOD FOR 
SIMULTANEOUS DETERMINATION OF ABIRATERONE AND ITS SEVEN 
STEROIDAL METABOLITES IN HUMAN SERUM 
 
 
 
2.1. Introduction to Liquid Chromatography Mass Spectrometry 
  Due to its sensitivity and selectivity, mass spectrometry-based analysis has been 
widely used in different types of research. It can be used to detect both small and large 
molecules. Mass spec applications include basic research, clinical research, drug discovery, 
forensics, food quality, and environmental protection. Several designs of mass 
spectrometers are available: linear ion trap, quadrupole based, time of flight (TOF). Also, 
there are hybrid designs: the quadrupole time of flight QTOF and quadrupole ion trap 
QTrap1.  Mass spec analysis allows one to answer numerous questions, including what is 
in the samples and how much of it is there. To be analyzed, the analyte should be charged, 
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because mass spec detects mass /charge ratio (m/z). The ionization techniques are electro 
spray ionization (ESI), atmospheric pressure chemical ionization, and atmospheric 
pressure photo ionization. The selection of the ionization type depends on the nature of the 
analyte. Multiple reaction monitoring is the technique that assures that only the analyte of 
interest is selected: First, analyzer quadrupole Q1 selects the precursor mass of interest 
from ions only of exactly the selected m/z pass to the collision cell Q2; all other ions are 
removed. Collision cell Q2 fragments precursor ions. Fragmented ions pass to analyzer 
quadrupole Q3. Analyzer quadrupole Q3 selects the most sensitive ion for quantitation 
(Fig. 6). Mass spectrometry can be used as a technique by itself or it can be coupled to 
liquid chromatography (LC-MS) or gas chromatography (GC-MS). Both techniques are 
widely used for metabolism studies; however the advantages of LC-MS over GC-MS 
includes simple sample preparation, shorter run times, and high throughput. 
Applying LC-MS analysis to detect analytes in human fluids (saliva, blood, serum, 
plasma, or urine) requires sample purification. Three methods can be applied to extract the 
analyte of interest from different matrices: direct protein precipitation, liquid-liquid 
extraction, or solid-phase extraction.     
LC-MS methods can be applied to prostate cancer research. As described in chapter 
I, prostate cancer depends on steroid synthesis. Therefore, using an LC-MS method that 
accurately detects these steroids and quantifies their levels in patient tissue or serum, may 
identify potential specific biomarkers2,3. LC-MS methods are useful in detecting drug 
metabolites; therefore it may also give a clue to which patients respond to treatment.     
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Figure 6. Multiple reaction monitoring principle. 
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2.2. Method Development and Validation 
Although mass spec is a useful technique, operating the instrument and developing 
the methods requires knowledge and qualifications in separation and ionization. The first 
step in developing LC-MS methods is to optimize mass spec parameters, which include 
selecting the appropriate ionization technique, selecting m/z for the parent analyte and the 
fragment, and selecting the declustering potential, collision energy, and the source 
temperature. After optimizing source parameters, the next step is to select suitable 
chromatographic conditions, which include type of analytical column, mobile phase 
composition, flow rate, and injection volume. Then as a last step, the best method of 
extraction is selected that leads to high recovery and minimizes the matrix effect. 
Depending on the purpose of analysis the development may also include selecting the linear 
range. After testing the developed method for linearity and accuracy, the next stage is 
validating the method per the guidelines depending on the type of analysis. The purpose of 
the validation is to make sure that the method is accurate and precise and the analytes are 
stable at different conditions. Once the validation is completed, the method is ready to be 
used for analysis. The development and validation steps are described in Figure 7.    
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Figure 7. The approach of developing LC-MS methods 
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2.3. Abiraterone Metabolism by Steroidogenic Enzymes 
Abiraterone design was based on its similarity in structure with pregnenolone which 
is a CYP17A1 substrate4,5. Since its FDA approval, abiraterone acetate, the prodrug of 
abiraterone, became the choice of treatment for patients with CRPC6,7. Abiraterone sulfate 
and N-oxide abiraterone sulfate are the reported abiraterone metabolites8. We studied the 
effect of steroidogenic enzymes on abiraterone both in vitro and in vivo and found that 3β-
hydroxysteroid dehydrogenase (3βHSD) converts abiraterone to its Δ4, 3-keto congener 
(Δ4-abiraterone; D4A)9. D4A is similar in structure to T which might enable further 
metabolism of D4A. D4A undergoes metabolism by two possible pathways: via steroid 5α-
reductase (SRD5A) or steroid 5β-reductase. The resultant metabolites can also be 
metabolized by two enzymes: 3α-hydroxysteroid dehydrogenase (3αHSD) or 3βHSD. The 
5α-reduced metabolites are 3-keto-5α-Abi, 3α-OH-5α-Abi and 3β-OH-5α-Abi, while the 
corresponding 5β-reduced metabolites are 3-keto-5β-Abi, 3α-OH-5β-Abi and 3β-OH-5β-
Abi10 (Fig 8). 
This chapter describes the development and validation of the LC-MS method that 
was used to detect abiraterone and its seven steroidal metabolites in human serum. In this 
validated method, the separation of the structurally identical metabolites was achieved 
using a reversed-phase chromatographic technique, not requiring a chiral column11.  All 
these metabolites were also detected in serum samples from patients with CRPC 
undergoing treatment with abiraterone acetate.   
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Figure 8. Steroidogenic enzyme metabolism of abiraterone. 
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2.4. Experimental Section 
2.4.1. Materials  
Abiraterone and its seven metabolites 3-keto-Δ4-Abi, 3-keto-5α-Abi, 3α-OH-5α-
Abi, 3β-OH-5α-Abi, 3-keto-5β-Abi, 3α-OH-5β-Abi and 3β-OH-5β-Abi were synthesized 
in the lab as described previously10. The internal standard (abiraterone-d4) was purchased 
from Toronto Research Chemicals, (Toronto, Canada). LC-MS grade methanol, 
acetonitrile, water, and formic acid were used to prepare the mobile phase and were 
purchased from Fisher Scientific (Fair Lawn, NJ); methyl tertiary butyl ether (MTBE) was 
used as the extraction solvent was HPLC grade and was purchased from Acros (Pittsburgh, 
PA). The control calibrators and all validation samples were prepared by spiking a known 
concentration of all analytes in double charcoal-stripped human serum from Golden West 
Biological Inc. (Temecula, CA).  
2.4.2. Method development 
In this section the development of LC-MS based bioanalytical method is described. 
The approaches to develop the LC-MS method involve optimizing the mass conditions and 
the chromatographic conditions, selecting linear range, and the procedure to prepare the 
sample, all of which are described in detail. 
2.4.2.1. Instrumentation and data analysis 
To analyze the samples, ultra-pressure liquid chromatography coupled to a mass 
spectrometer UPLC-MS system was used. The UPLC system (Shimadzu Corporation, 
Japan), consisted of an LC-30AD solvent delivery system, a DGU-20A5R vacuum 
degasser, a CTO-30A thermostated column oven, SIL-30AC auto-sampler, and a system 
CBM-20A controller. The UPLC system was coupled with a Qtrap 5500 mass spectrometer 
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(AB Sciex, Redwood City, CA). Data acquisition and processing were performed using 
Analyst software (version 1.6.2) from AB Sciex. The peak area ratio of the analyte over 
the internal standard was used for quantification purposes.  
2.4.2.2. Optimizing mass spectrometer conditions 
The mass spectrometer was operated in positive ion mode using an electrospray 
ionization (ESI) source, and applying multiple reaction monitoring (MRM). Tuning 
parameters were optimized for the abiraterone metabolites and internal standard by 
infusing a solution containing 200 ng/mL of each analyte. After infusing the solution and 
selecting the parent ion in Q1, the optimum value of the ion spray voltage, the source 
temperature, and the declustering potential were selected. Then the parent ion was 
fragmented in Q2 and the fragment ion (daughter ion) was selected along with the collision 
energy, entrance potential, and collision exit potential. The mass spectrometer parameters 
were optimized to ensure that the highest sensitivity possible would be achieved. Nitrogen 
was used as the nebulizing and drying gas.  
2.4.2.3. Optimizing chromatographic conditions 
Selecting an appropriate analytical column and a suitable mobile phase are the main 
factors in optimizing the chromatographic conditions. This will lead to an enhanced peak 
shape, increase in the intensity, and most importantly avoid overlap between analytes. In 
the case of diaseteoisomers, distinguishing between the metabolites based on their mass 
transition is very difficult because they share the same mass transition. Therefore, the 
chromatographic conditions are key in distinguishing between the metabolites. Chiral 
columns are the choice in dealing with diasterioisomers; however, these types of columns 
are not universal and require lot of trial and error experimentation. The challenge here was 
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to separate the metabolites using a regular C18 analytical column. Several mobile phases 
were evaluated with different compositions of organic modifiers or additives. The 
separation also depends on the column temperature, so this factor was also evaluated. 
2.4.2.4. Optimization of sample preparation  
When dealing with biological samples, the major factor in selecting the extraction 
protocol is the recovery of the analyte and also avoiding the matrix effect. Although direct 
protein precipitation is fastest and the cheapest, the matrix effect can be an issue and can 
lead to ion suppression during the analysis. Solid phase extraction is a useful technique but 
it is expensive and requires a long sample processing time. Therefore, here, liquid-liquid 
extraction procedure was considered from the beginning and optimized to obtain a high 
recovery and clean samples. Methyl tert butyl ether was selected as the organic solvent. 
The other solvent that was tested during the extraction was the reconstitution solvent.       
2.4.3. Method validation 
The developed method was then validated to check its accuracy, precision, 
robustness and rigidity.  The method was validated per US FDA guidance for bioanalytical 
method validation. The validation parameters evaluated were linearity, accuracy and 
precision, selectivity, recovery, matrix effect, and stability. 
2.4.3.1. Linearity 
To ensure that the selected range is suitable for analysis, six calibration curves were 
constructed in same serum matrix for each analyte. The calibration curve is the plot of the 
ratio of the analyte peak area over the internal standard peak area versus the nominal 
concentration. Linear regression was selected applying a weighting factor of 1/x. The FDA 
guidelines state that for lower limit of quantitation LLOQ the acceptable deviation from 
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the nominal concentration is < 20% and < 15% for the other calibration points and that 
67% of the calibrators, including LLOQ and upper limit of quantitation ULOQ, being 
within these acceptance criteria. 
2.4.3.2. Accuracy, precision, and sensitivity 
Five quality control (QC) samples from each level and LLOQ were run to determine 
intra-day accuracy and precision. To study the inter-day accuracy and precision, five QC 
samples from each level were prepared on 3 separate days and run immediately on the 
instrument after preparation. Accuracy was determined by how close the mean of the intra-
day QC sample results were to the nominal value. The method is considered accurate if the 
measured concentration is within 85%-115% (80%-120% for LLOQ) of the expected 
value.  The acceptable precision criterion is a coefficient of variation (CV%) of the QC 
sample analyte concentration being no more than 15% (LLOQ not more than 20%). 
2.4.3.3. Selectivity 
A selectivity test was done to ensure that the samples were free of interference. Six 
different serum batches were used to prepare blank and LLOQ samples. The LLOQ peak 
height (or peak area) must be at least 5 times of any peak detected in the corresponding 
blank samples at the same retention time of the analyte in order to be considered free from 
interference. 
2.4.3.4. Recovery 
The efficiency of the extraction protocol was evaluated through the recovery test. 
Three QC samples (low, mid, and high) were prepared pre- and post-extraction in triplicate. 
The analyte/internal standard peak area in spiked samples before extraction over the 
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analyte/internal standard peak area in spiked samples after extraction was used to calculate 
the relative recovery. There is no limit for the recovery; however, the results need to be 
consistent, precise and reproducible, as assessed by the coefficient of variation for each QC 
sample type being no more than 15%. The CV% was calculated as CV % = 
[(DX/X)2+(DY/Y)2)]1/2, where DX is the standard deviation for the pre-extraction samples, 
X is the mean area ratio of pre-extraction samples, DY is the standard deviation for the 
post-extraction samples, and Y is the mean area ratio of post-extraction samples. 
2.4.3.5. Matrix effect 
The matrix effect is the variability in analyte response due to the sample matrix. To 
evaluate the matrix effect, QC low was prepared in triplicate in six different serum batches. 
Matrix effect, calculated as a matrix factor percent (MF%), was calculated as follows: ratio 
of peak area ratio of spiked analyte/internal standard for the QC low samples after 
extraction (n=18) over the peak area ratio of the spiked analyte/internal standard in 
methanol: H2O, 1:1 (n=3).  CV% was calculated as described in section 2.4.3.4. 
2.4.3.6. Stability 
The stability test was done to ensure that the analytes were stable in solution and in 
the matrix under different conditions. To study the stability in solution (methanol: H2O), 
LLOQ, ULOQ, and the internal standard were prepared and kept at room temperature for 
6 hours or at 4ºC for 9 days. The prepared samples were compared with freshly prepared 
samples from stock stored at -20ºC. The peak area was used to compare the samples and 
the test was performed in triplicate.   
In many cases the analytical run will last for more than 24 hours. To ensure that the 
processed samples were stable during the analytical run, post-preparative stability was 
  36 
studied by keeping 5 samples of each of the three QC levels for 43 hours at 4ºC. Six samples 
of each QC low and high were used to evaluate the stability in serum under different 
conditions -- keeping the samples on the bench at room temperature for 21 hours (“bench 
top stability”); subjecting the samples to three freeze-thaw cycles (24 h at -80ºC with thaw 
at room temperature; “freeze thaw stability”); storing the samples at -80ºC for 28 weeks 
(“long-term stability”). To evaluate the stability, the concentrations in these samples were 
compared to the nominal values by running freshly prepared calibration curves. The 
accuracy had to fall within the 85-115% acceptance criteria and the relative standard 
deviation RSD could not exceed 15%. 
2.4.4. Standards and quality control (QC)  
Abiraterone and its metabolites were dissolved in methanol to prepare the stock 
solution of each at a concentration of 1 mg/mL. The working standard was prepared by 
mixing the stock solutions in one flask and diluted using methanol:H2O at 1:1;  the final 
concentration of abiraterone was 5.0 µg/mL and 0.25 µg/mL for the other metabolites. 
Freshly prepared working standard was used to prepare the serum calibrators and serum 
QC samples, all of which contained appropriate concentrations of all the analytes. Quality 
control samples were prepared at three levels, QC Low (3x LLOQ), QC Mid (half ULOQ), 
and QC High, which is 80% of ULOQ. The final concentrations of the calibrators and 
serum QC samples are listed in Table 1. The internal standard stock (2 mg/mL) was 
prepared by dissolving the stock powder in 100% methanol and further diluting it with 
methanol:H2O at 1:1 to a final concentration of 2.5 μg/mL. Stock and working standard 
solutions were stored at -20°C, and the calibrators with QC samples were freshly prepared 
through the validation. 
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Table 1. Calibrators and quality control samples.  
Sample 
Volume of 
Working 
Standard (μL) 
Final 
Volume 
(mL) 
Final Concentration in Serum 
ng/mL 
Abiraterone Metabolites 
Calibrator 1 20 10 2 0.1 
Calibrator 2 40 10 4 0.2 
Calibrator 3 120 10 12 0.6 
Calibrator 4 300 5 60 3 
Calibrator 5 600 5 120 6 
Calibrator 6 1400 5 280 14 
Calibrator 7 2000 5 400 20 
QC Low 60 10 6 0.3 
QC Mid 1000 5 200 10 
QC High 1600 5 320 16 
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2.5. Results and Discussion 
2.5.1. Method development 
The challenge in the development of a comprehensive pharmacokinetic (PK) 
technique to determine parent drug and metabolites is to separate these compounds without 
compromising sensitivity and linearity. The goal here was to develop an LC-MS/MS 
method with an available column and reagents so the method can be adopted easily by 
anyone performing the same type of stereoisomer analysis.  Several mobile phases were 
evaluated, including different organic modifiers (methanol, acetonitrile and 
methanol/acetonitrile mixtures) at various concentrations in water, as well mobile phases 
containing ammonium formate and/or formic acid without organic modifier. The Prodigy 
Phenomenix C18 analytical columns were also evaluated. Optimization of sample 
preparation according to recovery was also performed, various volumes of MTBE, as well 
as evaluating acidic and neutral reconstitution solutions. The best method was then selected 
based on the separation of all metabolites as well as based on the analytical qualities of 
linearity and sensitivity. 
2.5.1.1. Optimization of the mass analyzer  
Because of the steroidal nature of these metabolites and the presence of a pyridyl 
moiety, the mass analyzer was operated with electrospray ionization in the positive mode. 
The mass spectrometric parameters were optimized to ensure that the highest sensitivity 
possible would be achieved.  Nitrogen was used as the nebulizing (40 L/min) agent and 
drying gas (30 L/min). Ion spray voltage and the source temperature were regulated at 
2500 V and 500°C, respectively. All the analytes have the same declustering potential (120 
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V), collision energy (60 V), entrance potential (10 V) and collision exit potential (13 V). 
The metabolites mass transitions are given in Table 2. 
2.5.1.2. Optimization of the chromatographic conditions  
Due to the difficulty in distinguishing between the metabolites based on their MRM 
transition, we separated the metabolites (as well as the parent compound) by 
chromatography. Isocratic chromatographic conditions were optimized, investigating the 
effect of various mobile phase components at different concentrations. Separation of drug 
metabolites was achieved using a Zorbax Eclipse Plus C18 column 150 mm x 2.1 mm, 3.5 
µm (Agilent, Santa Clara, CA) at 40ºC with an isocratic mobile phase consisting of 35% 
A (0.1% formic acid in water) and 65% B (0.1% formic acid in methanol:acetonitrile 
(60:40), at a flow rate of 0.2 mL/min. Sample injection volume was 10 μL, and analytical 
run time was 13 minutes. Using the optimized chromatographic conditions resulted in 
separating the parent compound and metabolites, as shown in Figure 9. It should be noted 
that the method was able to resolve diastereomeric metabolites with a C18 column -- chiral 
columns were not required for separation of these stereoisomers. The employment of a 
methanol/acetonitrile mixture was critical to achieve this separation, as methanol or 
acetonitrile as the sole organic modifier in the mobile phase did not resolve the chiral 
compounds. 
2.5.1.3. Optimizing the sample preparation 
The metabolites were extracted from serum following liquid-liquid extraction. 
Different volumes of MTBE and various reconstitution solvents to achieve higher recovery 
and cleaner samples were tested. Each calibrator and QC sample was taken through the 
following sample preparation steps. Serum, 100 µL, with spiked analytes was placed in a 
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glass tube, and 20 µL 2.5 μg/mL internal standard working solution was added. The 
samples were vortexed for 30 seconds. After addition of 2 mL MTBE, the samples were 
vortexed for 1 minute. The samples were then centrifuged for 5 min at 4000 rpm at 4ºC. 
The organic layer was transferred to another tube and evaporated to dryness under nitrogen 
at 40ºC.  300 µL 1:1 methanol: H2O was used to reconstitute the dried extract and 200 µL 
was transferred to an HPLC vial. 
2.5.2. Method validation  
The method was validated according to FDA guidelines. As discussed below, all 
guideline criteria were met.  All the analytes were stable in solution and serum, meeting 
the stability criterion. The criteria for linearity, accuracy and precision fell within the 
acceptance criteria. The method gave excellent recovery without matrix effects or 
interference.  
2.5.2.1. Linearity  
To evaluate the linearity for each analyte six calibration plots were generated. 
Seven non-zero points were used to generate the calibration curve. The plot of the response 
ratio (analyte peak area over internal standard peak area) versus the analyte concentration 
was linear. The mean values for slope, intercept and R2 values for each analyte are listed 
in Table 3.  
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Table 2. Mass transition of abiraterone metabolites. 
Analyte Q1 (m/z) Q3 (m/z) 
Abiraterone 350.5 156.1 
D4A 348.3 156.1 
3-keto-5α-Abi 350.3 156.2 
3α-OH-5α-Abi 352.4 156.2 
3β-OH-5α-Abi 352.3 156.1 
3-keto-5β-Abi 350.4 156.1 
3α-OH-5β-Abi 352.4 156.4 
3β-OH-5β-Abi 352.1 156.1 
Abiraterone-d4 (IS) 354.4 160.1 
IS = internal standard 
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Figure 9. Chromatogram for abiraterone and its metabolites. The results were obtained 
by injecting 10 μL of 50 ng/mL standard solutions for A, Abi; B, D4A; C, 3-keto-5α-Abi; 
D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-Abi; and H, 3β-
OH-5β-Abi. 
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     Table 3. Mean values for slope, intercept and R2 
Analyte Slope Intercept R2 
Abiraterone 1.80E-02 8.17E-03 0.9990 
D4A 2.47E-02 3.00E-06 0.9996 
3-keto-5α-Abi 2.00E-02 1.04E-04 0.9995 
3α-OH-5α-Abi 2.16E-02 -6.33E-05 0.9995 
3β-OH-5α-Abi 2.56E-02 1.21E-04 0.9996 
3-keto-5β-Abi 1.15E-02 3.80E-05 0.9995 
3α-OH-5β-Abi 1.26E-02 -3.67E-05 0.9995 
3β-OH-5β-Abi 2.03E-03 5.00E-06 0.9991 
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2.5.2.2. Accuracy and precision 
To test the method’s accuracy and precision, five replicates of each QC sample 
were prepared on three different days. Five LLOQ samples were prepared in the first batch, 
and the intraday accuracy mean values were 85.3-111.2 %.  All the results fall within the 
FDA acceptance criteria. The measured concentrations (in ng/mL) and the results for inter- 
and intra-day precision and accuracy determination are given in Table 4. Nominal 
concentrations for abiraterone (LLOQ = 2, QC low = 6, mid = 200, and high = 320 ng/mL); 
and the nominal concentrations for the metabolites (LLOQ = 0.1, QC low = 0.3, mid=10, 
and high=16 ng/mL). 
2.5.2.3. Selectivity 
Testing of six LLOQ samples, each prepared from different serum batches, were 
compared to their blank samples showed that the serum was free from interference. The 
MRM chromatograms for the six representative blank samples compared to the MRM 
chromatograms of LLOQ samples of abiraterone and its 7 steroidal metabolites are shown 
in Figure 10.  
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Figure 10. Representative chromatogram of selectivity studies comparing blank samples 
(left chromatograms) matched to LLOQ (right chromatograms) for A, Abi; B, D4A; C, 3-
keto-5α-Abi; D, 3-keto-5β-Abi; E, 3α-OH-5α-Abi; F, 3α-OH-5β-Abi; G, 3β-OH-5α-Abi; 
and H, 3β-OH-5β-Abi. 
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Table 4. Intra- and inter-day accuracy and precision. 
Analyte 
Intra-day (n=5) Inter-day (n=15) 
Measured 
Concentration 
Accuracy 
% 
RSD 
% 
Measured 
Concentration 
Accuracy 
% 
RSD 
% 
Abiraterone 
2.05 102.7 2.89 n.a n.a n.a 
6.4 106.8 2.65 6.21 103.5 4.95 
203.8 102 2.06 206.3 103.3 2.84 
316 98.7 3.86 317 99.1 6.8 
D4A 
0.111 111.2 3.89 n.a n.a n.a 
0.307 102.3 7.76 0.297 98.9 6.68 
10.02 100.2 1.86 9.74 97.4 3.94 
16.4 102.3 3.02 16 100.1 6.35 
3-keto-5α-
Abi 
0.111 111 3.43 n.a n.a n.a 
0.322 107.4 1.56 0.301 100.1 7.86 
10.32 103.2 2.86 9.87 98.7 5.03 
16.8 104.9 4.68 16.5 103.1 7.56 
3α-OH-5α-
Abi 
0.106 106.2 9.23 n.a n.a n.a 
0.314 104.6 5.96 0.304 101.5 9.45 
9.91 99.1 4.41 9.39 93.9 6.33 
14.8 92.6 4.97 15.1 94.5 7.61 
3β-OH-5α-
Abi 
0.103 103 2.63 n.a n.a n.a 
0.305 101.5 4.21 0.301 100.3 4.66 
9.92 99.2 2.07 9.86 98.6 3.99 
16.0 99.9 4.63 16.1 100.6 6.51 
3-keto-5β-
Abi 
0.106 106.4 4.13 n.a n.a n.a 
0.316 105.4 2.56 0.303 101 8.77 
9.95 99.5 2.7 9.56 95.6 4.61 
15.1 94.2 3.61 15.5 96.5 7.8 
3α-OH-5β-
Abi 
0.108 108.4 4.26 n.a n.a n.a 
0.308 102.6 6.74 0.301 100.4 7.55 
9.74 97.4 2.98 9.37 93.8 4.26 
15.0 93.8 4.65 15.3 95.8 7.46 
3β-OH-5β-
Abi 
0.085 85.3 16.8 n.a n.a n.a 
0.275 91.7 10.7 0.29 97.6 12.1 
9.68 96.8 0.99 9.76 97.6 3.67 
14.9 93.3 5.6 16 99.7 9.66 
 
  47 
2.5.2.4. Recovery 
The three QC levels were used to study the relative recovery, which is determined 
by the percent ratio of the analyte/internal standard peak area of a spiked sample before 
extraction over the analyte/internal standard peak area of a spiked sample after extraction. 
The results should be consistent, precise, and reproducible. The recovery was calculated as 
the mean of three triplicates for each analyte at each QC level. Recovery results and the 
CV% were good and are given in Table 5. The results met the 15% CV% criterion for 
acceptable recovery. 
2.5.2.5. Matrix effect  
The matrix effect is quantified as a matrix factor percent (MF%) by calculating the 
peak area ratio of analyte/internal standard of a QC low sample (post-extraction addition 
of analyte) over the peak area ratio of analyte/internal standard in a methanol/water 
solution.  Matrix effect results are given in Table 5, showing that the technique is 
essentially free from interference.  
2.5.2.6. Stability 
Analytes were stable in the diluted solution stored at room temperature for 6 hours 
and at 4ºC for 9 days as given in Table 6. Results of serum-based stability studies 
employing QC samples are given in Table 7.  The samples were found stable when stored 
at the autosampler temperature at 4ºC for 43 h. The analytes were stable in serum when the 
samples were left on the bench for 21 h.  Even though all analytes did show a decrease in 
concentration when subjected to three freeze-thaw cycles or when stored at -80ºC  for 28 
weeks, the results were less than 15%, which is within the criteria for accuracy. 
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   Table 5. Matrix effect and recovery. 
Analyte 
MF % 
(n=18) 
Recovery %  
(n=3) 
QC low QC low QC Mid QC High 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
Mean 
(%) 
RSD 
(%) 
Abiraterone 114.7 5.04 95.7 6.54 91.7 1.49 93.4 4.65 
D4A 88.5 5.99 105.2 4.78 99.0 3.39 94.6 7.81 
3-keto-5α-Abi 96.1 5.22 91.6 7.47 89.1 7.62 97.7 9.12 
3α-OH-5α-Abi 92.0 5.05 91.2 7.48 85.1 4.51 95.1 5.61 
3β-OH-5α-Abi 99.4 4.57 88.5 6.87 86.9 2.12 92.1 5.78 
3-keto-5β-Abi 93.2 8.31 91.0 13.47 87.1 6.33 96.3 6.39 
3α-OH-5β-Abi 92.0 6.74 86.0 8.47 85.1 1.09 91.1 5.64 
3β-OH-5β-Abi 100.0 11.13 96.6 11.50 86.3 4.28 91.4 8.16 
    RSD% – relative standard deviation percent which is the same as CV%  
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      Table 6. Stock stability and post preparative stability. 
      RT – Room temperature 
 
 
 
 
 
 
 
 
 
 
Analyte 
6 Hours at RT 
(n=3) 
9 Days at 4⁰C 
(n=3) 
Post-Preparative 
42 Hr (n=5)  
LLOQ 
(%) 
ULOQ 
(%) 
LLOQ 
(%) 
ULOQ 
(%) 
QC 
Low 
QC 
Mid 
QC 
High 
Abiraterone 98.5 103.5 109.5 98.4 97.8 101.7 98.3 
D4A 100.2 102.4 91.1 86.9 96.7 96.1 100.3 
3-keto-5α-Abi 112.1 103.7 101.6 88.4 100.0 100.2 101.6 
3α-OH-5α-Abi 103.8 102.7 97.9 85.7 103.3 100.7 102 
3β-OH-5α-Abi 105.2 102.1 101.7 89.3 100.0 98.7 98.1 
3-keto-5β-Abi 107.6 103.7 97.5 83.2 103.3 101.7 102 
3α-OH-5β-Abi 104.1 103.3 105.0 85.4 100.0 96.2 97.5 
3β-OH-5β-Abi 115.0 104.6 95.4 89.7 103.3 98.2 100.4 
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 Table 7. Stability in serum. 
Analyte  
Short-term 
21 hr 
Freeze- thaw 
3 cycles 
Long-term 
28 weeks 
QC 
 Low 
QC 
 High 
QC 
 Low 
QC 
 High 
QC 
 Low 
QC 
  High 
Abiraterone 
Concentration 5.3 293.8 5.4 284.9 5.7 290.7 
Accuracy % 88.2 91.8 89.5 89 95.5 90.8 
% RSD 6.03 1.97 11.38 9.45 0.82 2.28 
D4A 
Concentration 0.3 18.4 0.3 15.3 0.3 14.2 
Accuracy % 100 114.8 86.7 95.8 90 88.6 
% RSD 3.03 1.86 8.82 11.71 3.64 1.42 
3-keto-5α-Abi 
Concentration 0.3 15.7 0.3 14.7 0.3 14.4 
Accuracy % 93.3 98.1 86.7 91.6 86.7 90.1 
% RSD 8.04 2.57 12.84 14.11 5.9 5.59 
3α-OH-5α-Abi 
Concentration 0.3 15.8 0.3 14.1 0.3 14.2 
Accuracy % 96.7 98.7 86.7 88.2 86.7 88.6 
% RSD 7.16 3.4 9.82 14.26 7.32 4.34 
3β-OH-5α-Abi 
Concentration 0.3 15.2 0.3 13.9 0.3 14.1 
Accuracy % 90 95.1 86.7 86.7 86.7 87.9 
% RSD 10.28 2.22 14.55 11.27 4.58 2.5 
3-keto-5β-Abi 
Concentration 0.3 16.3 0.3 14.2 0.3 14.4 
Accuracy % 100 101.8 93.3 88.9 86.7 90.1 
% RSD 7.58 3.66 14.57 13.44 4.92 4.26 
3α-OH-5β-Abi 
Concentration 0.3 16.1 0.3 13.8 0.3 15 
Accuracy % 96.7 100.8 86.7 86.3 90 93.5 
% RSD 7.77 2.29 10.66 12.19 3.65 3.53 
3β-OH-5β-Abi 
Concentration 0.3 16.5 0.3 14.4 0.3 14.7 
Accuracy % 93.3 103 96.7 89.8 93.3 91.9 
% RSD 10.44 5.3 14.41 13.84 5.21 3.56 
     RSD% = relative standard deviation % is the same as CV%;  
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2.6. Conclusions 
In this chapter an LC-MS/MS MRM method for the determination and accurate 
quantification of abiraterone and its metabolites in human serum was developed and 
validated.  This is the first report of a method to determine abiraterone metabolites that 
result from steroidogenic metabolism. The validated LC-MS/MS method resolved and 
quantitated all the metabolites despite the similarity in their structures, including resolving 
diastereomers, a situation that precludes analysis of co-eluting isomers based solely on 
their MRM transitions. Reversed-phase chromatographic conditions were identified to 
accomplish the separation of all metabolites and their subsequent accurate quantification. 
This validated method can be applied to determine abiraterone and the aforementioned 
metabolites in human serum in clinical trials in which patients are treated with abiraterone 
acetate.  
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CHAPTER III 
DETERMINATION OF ABIRATERONE METABOLITES IN VITRO AND IN 
VIVO 
 
 
 
3.1. Development of Abiraterone 
When abiraterone was first studied in 19941, it decreased circulating testosterone 
levels and reduced the weights of androgen-dependent organs in mice. It was designed 
based on the structure of pregnenolone, which is a substrate of CYP17A1. In the early 
stages of abiraterone development, several structurally related compounds were studied 
and compared with ketoconazole which was widely used as a CYP17A1 inhibitor. The 3β-
hydroxy, Δ5 steroidal structure with a 3 pyridyl ring at C17 and the 16, 17 double bond was 
10 times more potent than ketoconazole in inhibiting CYP17A12. The 16, 17 double bond 
was reported to be necessary for the irreversible inhibition of CYP17A13.  The x-ray crystal 
structure of CYP17A1 binding to abiraterone shows that abiraterone binds to heme iron.4 
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Abiraterone was reported to inhibit 3βHSD either at high concentration or when 
administered with food 5,6. Abiraterone is administered in patients as the prodrug 
abiraterone acetate (AA) in combination with prednisone 7-9.  
Until recently, the main reported abiraterone metabolites were abiraterone sulfate 
and N-oxide abiraterone sulfate.10 Recently, Li et al11,12 reported a new pathway of 
abiraterone metabolism by steroidogenic enzymes. They studied the metabolism both in 
vitro and in vivo and were able to identify seven steroidal metabolites that were generated 
from abiraterone13. They studied the effect of the generated metabolites and showed that 
some of the abiraterone steroidal metabolites are biochemically active and had a crucial 
function in prostate cancer.  
3.2. Experimental Section 
3.2.1. Materials 
Iscove’s Modified Dulbecco’s (IMDM), Roswell Park Memorial Institute (RPMI) 
1640 and Dulbecco’s Modified Eagle’s (DMEM) media were all purchased from (Sigma-
Aldrich, St. Louis, MO).  Fetal Bovine Serum (FBS) from Gemini (West Sacramento, CA). 
VCaP cells were purchased from the American Type Culture Collection (Manassas, VA). 
C4-2 cells were kindly provided by Dr. Leland Chung (Cedars-Sinai Medical Center, Los 
Angeles, CA) and maintained in RPMI-1640 with 10% FBS. The LAPC4 cell line was 
kindly provided by Dr. Charles Sawyers (Memorial Sloan Kettering Cancer Center, New 
York, NY) and grown in IMDM with 10% FBS. All experiments done with VCaP cells 
were done in plates coated with poly-DL-ornithine (Sigma-Aldrich, St. Louis, MO). Cell 
lines were authenticated by DDC Medical (Fairfield, OH) and determined to be 
mycoplasma-free with primers 5’-ACACCATGGGAGCTGGTAAT-3’ and 5’-
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GTTCATCGACTTTCAGACCCAAGGCAT3’. All reagents used to run the LC-MS are 
listed in section 2.4.1. 
3.2.2. In vitro metabolism of abiraterone  
To test the hypothesis that steroidogenic enzymes present in prostate cancer cell 
lines can convert abiraterone to its steroidal metabolites, LC-MS analyses were performed 
to analyze samples obtained from in vitro assays using prostate cancer cell lines with 
known enzymatic activity: C4-2 with high 3βHSD enzymatic activity and VCaP and 
LAPC4 which have a robust SRD5A1 activity and a low 3βHSD enzymatic activity.   Cells 
were seeded and incubated in 12-well plates with 0.2 million cells/well for ~24 h and then 
incubated with 1µM of abiraterone, D4A, 3-keto-5α-Abi, 3α-OH-5α-Abi, 3β-OH-5α-Abi, 
3-keto-5β-Abi, 3α-OH-5β-Abi or 3β-OH-5β-Abi, for 24 and 48 hr. Media was collected at 
the two time points and were subjected to LC-MS analysis. This experiment was performed 
in triplicate for each drug and was repeated for three biological repeats.  
3.2.3. Abiraterone metabolism in mice 
To confirm that abiraterone is metabolized by steroidogenic enzymes, LC-MS 
analysis was utilized to confirm the metabolism in mice. Male NSG mice, 6 to 8 weeks of 
age were obtained from the Cleveland Clinic Biological Resources Unit facility. All mouse 
studies were conducted under a protocol approved by the Cleveland Clinic Institutional 
Animal Care and Use Committee. Mice were injected intraperitoneally with 100 µL 
solution containing 0.15 mmol/kg of either abiraterone (n=5), D4A (n=5), 3-keto-5α-Abi 
(n=4), 3α-OH-5α-Abi (n=4), or 3β-OH-5α-Abi (n = 4 mice/group). Blood was collected 2 
and 4 hrs after injection, centrifuged at 10,000 rpm, and the sera were stored at -80ºC for 
LC-MS analysis.   
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3.2.4. Pharmacokinetics of abiraterone and its steroidal metabolites in human  
The activities conferred by steroidal metabolites of abiraterone may make them 
biomarkers of clinical response or treatment resistance. To study the pharmacokinetics 
(PK) of abiraterone and its seven steroidal metabolites in humans, plasma samples from a 
clinical trial led by Janssen Pharmaceuticals were analyzed. In this pharmacokinetics study, 
15 healthy male volunteers received a single oral dose of 1000 mg abiraterone acetate plus 
240 mg of the AR antagonist apalutamide under fasting conditions. Serial plasma samples 
were collected from each volunteer to cover the period from 0-96 hours post-dose as 
follows: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, and 96 hours. Aliquots of the plasma 
samples were subjected to LC-MS analysis to quantify the concentrations of abiraterone 
and its seven structurally related steroidal metabolites and to assess the pharmacokinetics 
parameters for each of the metabolites.  
3.2.5. LC-MS analysis 
All samples collected from cell metabolism, mouse metabolism, and the 
pharmacokinetics studies were subjected to LC-MS analysis. All the analyses were 
performed using the same mass spectrometer conditions and chromatographic conditions; 
the only difference was the sample preparation procedure. The cell metabolism sample 
preparation was as follows: To 200 µL media 40 µL internal standard (abiraterone-d4) was 
added and  then the analytes were extracted with 2 ml TMBE,  the TMBE was evaporated, 
and the remaining sample was  reconstituted with 200 µL methanol:H2O; 1:1. The standard 
curves were prepared in media. Samples obtained from mice were subjected to direct 
protein precipitation as follows: To 20 µL mouse serum, 180 µL methanol containing the 
IS was added; the sample was centrifuged at 10,000 g for 10 min, and then 120 µL 
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supernatant was transferred to HPLC vials. The standard curves were prepared in drug-free 
mouse sera. The pharmacokinetic samples were prepared as follows: 100 µL of human 
plasma was spiked with 20 µL IS, 2 ml of TBME was added, the samples were then 
vortexed and centrifuged. The organic layer was evaporated and the samples were 
reconstituted with 300 µL methanol:H2O; 1:1.   
3.3. Results and Discussion 
3.3.1. Cell metabolism 
3βHSD enzymatic activity is present in the C4-2 cell line; therefore treating the 
cells with abiraterone resulted in detection of the abiraterone downstream metabolites as 
shown in Figure 11A. When the cells were treated with D4A, the downstream metabolites 
also were detected but not abiraterone itself (Fig 11B). This indicates that 3βHSD activity 
is not reversible and D4A was fully consumed and metabolized after 48 hours. Treating 
the cells with any of the 5α-reduced metabolites resulted in detecting the other two 5α-
reduced metabolites (Fig. 11C-E). This behavior was not observed with 5β-reduced 
metabolite. Only when the cells were treated with 3-keto-5β-Abi all three 5β reduced 
metabolites were detected (Fig. 11F).  However, treating the cells with either 3α-OH-5β-
Abi or 3β-OH-5β-Abi did not result in detecting all 5β-reduced metabolites (Fig. 11G&H). 
In the C4-2 cell line as well as VCaP and LAPC4 cells, 5β-reductase enzymatic activity is 
absent. Therefore, only 5α-reduced metabolites were detected when cells were treated with 
abiraterone or D4A. In contrast to C4-2, LAPC4 and VCaP cell line have low 3βHSD 
activity. Therefore, treating the cells with abiraterone resulted in low yield of the 
downstream metabolites (Fig. 12A &13A). D4A treatment in the two cell lines resulted in 
high yield of the 5α-reduced metabolites which substantiates their robust SRD5A1 activity 
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(Fig. 12B &13B). In VCaP and LAPC4 cells, the conversion of the 5α reduced metabolites 
was not interchangeable (Fig. 12C-E &13C-E) due to low 3βHSD activity, which is 
responsible for converting 3β-OH-5α-Abi back to 3-keto-5α-Abi. 3-keto-5β-Abi 
conversion was fast, with only 20% and 30% of the metabolites left in the media after 24 
hours and almost nothing left after 48 hours (Fig. 12F&13F).  Treating the cells with 3α-
OH-5β-Abi did not result in detecting any of the other 5β-reduced metabolites (Fig 
12G&13G). In VCaP cells within 24 hours, 20% of 3β-OH-5β-Abi was converted to 3α-
OH-5β-Abi.  However, in LAPC4 cells it took 48 hours to reach this percentage (Fig 
12H&13H).  Together all these results suggest that steroidogenic enzymes are responsible 
for the metabolism and formation of abiraterone steroidal metabolites and that once the 
metabolites are formed, they cannot be converted back to abiraterone.  
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Figure 11. Metabolism of abiraterone and its metabolites in C4-2 cells. A, Abi; B, D4A; 
C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-
Abi; and H, 3β-OH-5β-Abi. 
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Figure 12. Metabolism of abiraterone and its metabolites in VCaP cells. A, Abi; B, D4A; 
C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-
Abi; and H, 3β-OH-5β-Abi. 
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Figure 13. Metabolism of abiraterone and its metabolites in LAPC4 cells. A, Abi; B, 
D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-
OH-5β-Abi; and H, 3β-OH-5β-Abi. 
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3.3.2. Abiraterone in vivo metabolism 
To confirm that the metabolism occurs in mice, a PK experiment was performed. 
Blood samples were collected 2 and 4 hr after the metabolite injection into NSG mice. The 
LC-MS analysis of mouse sera showed that abiraterone metabolism was fast: by 2 hrs after 
abiraterone injection, more than 40% was converted to the downstream metabolites, 
including the 5β-reduced metabolites (Fig 14A). In contrast, in the group of mice injected 
with D4A, the metabolism of D4A was not fast: only 20% was converted to the downstream 
metabolites after 4 hrs (Fig 14B). This could be due to the inhibitory effect of D4A on 
steroidogenic enzymes. Similar to the cell lines, conversion of the three 5α-reduced 
metabolites is reversible; injecting any of the 5α-reduced metabolites resulted in detecting 
all three of them but not abiraterone, D4A, or any of the 5β-reduced metabolites (Fig 14C-
E). The favorite reduction pathway for 3-keto-5α-Abi is through 3α-HSD to produce 3α-
OH-5α-Abi, as 45% of 3-keto-5α-Abi was converted (Fig 14C). In the other hand, the 
reversible reaction was slow: less than 10% of 3α-OH-5α-Abi was converted to 3-keto-5α-
Abi. However, the 3β-OH-5α-Abi metabolite when injected into the mice resulted in the 
formation of both 3-keto-5α-Abi and 3α-OH-5α-Abi. All these results suggest that 
abiraterone metabolism occurs fast in mice and that none of the metabolites can generate 
abiraterone. 
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Figure 14. In vivo metabolism of abiraterone and its metabolites in NSG mice. A, Abi; B, 
D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi. 
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3.3.3. Pharmacokinetics studies in humans 
Abiraterone bioavailability was reported to be highly variable14. However, little is 
known about steroidal metabolites of abiraterone regarding the temporal nature of their 
formation and elimination that would inform the timing of metabolite sampling for 
biomarker studies. Analysis of pharmacokinetics samples from 15 healthy volunteers 
confirmed that not just abiraterone but its metabolites were also variable.  All the 
metabolites were detected in the volunteers. The results in Figure 15A-H show the 
variability of the metabolite concentrations in the volunteers.  The drop in the mean 
percentage of abiraterone over time is accompanied by a rise in the 5β-reduced metabolites 
(Fig 16). The pharmacokinetics analysis was performed assuming a non-compartmental 
model. The metabolite maximum concentration was achieved between 1.9-19.3 hours. The 
mean Tmax was 1.9 hr for abiraterone, 2.1 hr for D4A, and 2.7 hr for 3-keto-5α-Abi, and 
ranged between 3.2 and 19.3 hrs for the other metabolites (Table 8). The mean Cmax was 
90 ng/ml for abiraterone, 0.91 ng/ml for D4A, and 5.5 ng/ml for 3-keto-5α-Abi (Table 9). 
The mean AUC at 96 hrs ranged from 5.0 for 3β-OH-5α-Abi to 504 for abiraterone (Table 
10). These data suggest that abiraterone metabolism via steroidogenic enzymes takes place 
rapidly and that D4A and 3-keto-5α-Abi are generated in rapid succession from the first 
abiraterone dose. This is the first study to evaluate the pharmacokinetics parameters of 
abiraterone and its seven steroidal metabolites in healthy volunteers, and these data will 
help in designing biomarker studies of abiraterone metabolite levels to enhance clinical 
treatment.  
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Figure 15. Pharmacokinetics of abiraterone metabolites in human serum. 15 healthy 
individual (color coded) draw blood up to 96 h after single dose of abiraterone acetate. A, 
Abi; B, D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; 
G, 3α-OH-5β-Abi; and H, 3β-OH-5β-Abi. 
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Figure 16. The mean percentage of abiraterone metabolites in human serum at 12 time 
points to cover the period (0.5-96 h) 
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Table 8. Tmax (hours) for abiraterone metabolites. 
Analyte Min 25th Percentile Median 
75th 
Percentile Max Mean SEM 
Abiraterone 1.0 1.5 1.5 2.0 4.0 1.9 0.23 
D4A 1.0 1.5 2.0 2.0 4.0 2.1 0.22 
3-keto-5α-Abi 1.5 2.0 2.0 4.0 4.0 2.7 0.28 
3α-OH-5α-Abi 4.0 4.0 4.0 6.0 8.0 5.1 0.38 
3β-OH-5α-Abi 0 4.0 4.0 4.0 6.0 3.7 0.33 
3-keto-5β-Abi 1.5 1.5 2.0 4.0 12 3.2 0.72 
3α-OH-5β-Abi 2.0 4.0 8.0 24 72 19.3 5.46 
3β-OH-5β-Abi 6.0 8.0 12 24 48 16.8 2.92 
 
 
 
 
 
 
 
 
 
 
 
 
  69 
 
 
 
Table 9. Cmax (ng/ml) for abiraterone metabolites. 
Analyte Min 25th Percentile Median 
75th 
Percentile Max Mean SEM 
Abiraterone 33.8 38.3 65.5 116.7 223.3 90.1 15.2 
D4A 0.43 0.57 0.81 1.31 2.12 0.91 0.12 
3-keto-5α-Abi 1.18 2.76 4.59 6.72 22.6 5.54 1.33 
3α-OH-5α-Abi 0.16 0.44 0.76 1.47 4.07 1.06 0.25 
3β-OH-5α-Abi 0.00 0.15 0.23 0.49 1.84 0.39 0.11 
3-keto-5β-Abi 0.63 1.13 1.32 1.85 3.53 1.51 0.18 
3α-OH-5β-Abi 0.44 0.90 1.19 1.77 3.02 1.41 0.18 
3β-OH-5β-Abi 0.91 2.58 3.14 6.91 10.5 4.55 0.75 
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Table 10. AUC at 96 hours for abiraterone metabolites. 
Analyte Min 25th Percentile Median 
75th 
Percentile Max Mean SEM 
Abiraterone 165 233 322 596 1784 504 110 
D4A 2.59 6.21 8.83 10.5 18.7 8.86 1.14 
3-keto-5α-Abi 9.46 25.7 40.4 54.7 235 52.7 13.85 
3α-OH-5α-Abi 1.99 4.98 8.81 16.8 63.4 14.3 3.88 
3β-OH-5α-Abi 0.00 0.75 1.51 5.87 31.5 5.04 2.10 
3-keto-5β-Abi 1.69 14.0 19.7 41.6 57.9 27.0 4.45 
3α-OH-5β-Abi 20.1 44.2 52.1 103 162 70.6 10.21 
3β-OH-5β-Abi 22.8 99.3 128 320 455 188 34.77 
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3.4. Conclusion 
Until recently, very little was known about steroidogenic metabolism of 
abiraterone. The work presented here demonstrates that steroidogenic enzymes metabolize 
abiraterone to at least seven new compounds. The formation of the metabolites was fast as 
confirmed by in vitro and in vivo experiments. Conversion of abiraterone and D4A to 
downstream metabolites was irreversible. This was confirmed by showing that the 
accumulation of products did not drive flux to their precursors (in this case abiraterone and 
D4A). In healthy human subjects, the metabolism was also fast, and all the metabolites 
were detected from the first dose of abiraterone acetate. All these data confirmed the 
presence of a previously unappreciated novel pathway of abiraterone metabolism.      
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CHAPTER IV 
ABIRATERONE METABOLISM IN PATIENTS WITH CASTRATION-
RESISTANT PROSTATE CANCER 
 
 
 
4.1. Background 
Prior to its approval in 2011, abiraterone acetate went through several clinical trials 
to evaluate its efficacy, safety, and the dose. The first study, which was three small clinical 
trials, was reported in 2004 1. In these trials the major objective was to determine the dose 
that will result in maximum suppression of testosterone; the other objectives include safety 
and tolerability, pharmacokinetics, and evaluating some endocrine data. The second 
clinical trial was reported in 2008 2; it was a phase I/II clinical study with escalating dose 
of abiraterone acetate to evaluate drug safety, pharmacokinetics, and activity in 
chemotherapy-naive patients with CRPC. Based on the outcomes of this study, the selected 
dose for treatment in clinical practice was 1000 mg daily. The major side effects were 
associated with the blockade of CYP17A1 activity; which lowers glucocorticoid and 
  75 
elevates mineralocorticoid levels. The side effects included hypertension, hypokalemia, 
and fluid retention, which were managed with a mineralocorticoid antagonist, and can be 
prevented when abiraterone acetate is administered with prednisone. Other clinical trials 
evaluated abiraterone acetate after ketoconazole3 or in patients with prior treatment with 
chemotherapy4,5. Phase III trials were double-blind, placebo-controlled, multicenter 
designs for patients with prior chemotherapy (COU-AA-301)6  or chemotherapy-naive 
CRPC patients (COU-AA-302) 7. Based on the outcome of these two clinical trials for 
CRPC treatment, the US FDA approved abiraterone acetate in combination with 
prednisone to treat CRPC patients before or after chemotherapy. Since its approval, 
updated trial results have been published -- the median overall survival was 15.2 in 
abiraterone acetate plus prednisone arm, compared to 11.8 in the placebo plus prednisone 
arm for (COU-AA-301)8. Median overall survival was 34.7 months in the abiraterone 
group vs 30.3 months in the control group (COU-AA-302)9. 
As discussed in Chapter 3, abiraterone metabolism in vitro and in vivo generated at 
least seven metabolites through steroidogenic enzyme activity. The metabolites were also 
present in healthy humans in a clinical trial to evaluate the PK parameters after single dose 
of abiraterone acetate. Abiraterone metabolites play an important role in prostate cancer. 
D4A is the first downstream metabolite and inhibits the following steroidogenic enzymes: 
CYP17A1, 3βHSD1, and SRD5A1. It also inhibits expression of the AR-responsive genes: 
prostate-specific antigen (PSA), TMPRSS2, and FKBP5. In vivo, D4A inhibits tumor 
progression in xenograft mice when compared to abiraterone acetate10.  However further 
metabolism of D4A will not only result in losing its effect, it will generate 3-keto-5α-Abi 
which stimulates the expression of AR-responsive genes and promotes tumor progression 
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in xenograft mice11. Thus, it was important to determine the metabolite levels in patients 
treated with abiraterone acetate.  
This chapter focuses on determining abiraterone metabolites in several clinical 
trials that included investigation of the effect increasing the frequency of abiraterone 
acetate dose or adding steroidogenic enzyme inhibitors on abiraterone metabolism. In the 
first trial CRPC patients received a standard dose of abiraterone acetate (1 gm daily) with 
5 mg twice daily of prednisone (a drug administered with abiraterone acetate to overcome 
adverse events). In the second study, 1 gm daily of abiraterone acetate was combined with 
leuprolide acetate (an LHRH agonist)12. The third study combined abiraterone acetate with 
prednisone and dutasteride (a SRD5A1 inhibitor that is used to treat benign prostate 
hyperplasia)13. The fourth and last trial was designed to study the effect of increasing the 
abiraterone acetate dose from 1 gm daily to 1 gm twice daily. Samples from the four trials 
were obtained and subjected to LC-MS analysis to measure the metabolite levels.  
4.2. Determination of Abiraterone Metabolism in Clinical Trials 
The common aim of these trials was to maximize the benefit of abiraterone 
treatment. None of these trials had a major objective to study abiraterone metabolism; 
however, one of the approaches to achieve the goals of these trials was through determining 
abiraterone metabolites and correlating them with clinical outcomes.    
4.2.1. CRPC patients treated with standard dose of abiraterone acetate  
  In a clinical study held at the Cleveland Clinic under an Institutional Review Board 
– approved protocol (Case 7813), CRPC patients received a standard dose of abiraterone 
acetate (1gm daily) and 5mg twice daily of prednisone on an outpatient basis. The primary 
objective of this research study was to identify the biochemical mechanisms that underlie 
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resistance to hormonal therapies in advanced prostate cancer and to define the underlying 
mechanisms. One of the approaches was to determine abiraterone metabolites in the sera 
of the patients and correlate the levels with the clinical outcomes.  The time from the daily 
dose to the blood draw was recorded. Blood was collected using Vacutainer Plus serum 
blood collection tubes (#BD367814, Becton Dickenson, Franklin Lakes, NJ). Blood was 
collected between 1 and 16 hours after the daily dose of abiraterone acetate was 
administered. Blood was allowed to clot and tubes were centrifuged at 2500 rpm for 10 
minutes.  Serum aliquots were frozen at -80°C until processing. 
4.2.2. Neoadjuvant study of abiraterone in combination with an LHRH agonist  
This clinical trial (NCT00924469) was a phase II open-label, randomized, multi-
center study of neoadjuvant abiraterone acetate plus leuprolide acetate (an LHRH agonist) 
and prednisone versus leuprolide acetate alone in men with localized high-risk prostate 
cancer performed at Dana Farber Cancer Institute; and all patients provided written 
informed consent. The patients received the treatment for 24 weeks and then underwent 
surgery (prostatectomy). On the day of surgery, a blood sample also was drawn. The major 
aim of this trial was to evaluate the safety and efficacy of the combined treatment. 
However, for the purpose of this research, abiraterone and the metabolite levels were 
compared in both the prostate tissue and serum and were correlated with the clinical 
outcome. 
4.2.3. Effect of increasing frequency to abiraterone acetate 
This was a single arm, open–label, multicenter, phase II study conducted at the 
University of California San Francisco UCSF and Oregon Health and Science University 
OHSU. The study was approved by UCSF and OHSU Institutional Review Boards and all 
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patients provided written informed consent prior to participation. The trial aim was to 
evaluate the efficacy and safety of increasing abiraterone acetate dose in chemotherapy-
naïve CRPC patients3. All patients started with the standard dose of abiraterone acetate and 
prednisone until the PSA concentration increased by 25% above nadir or until clinical or 
radiographic progression. At the time of disease progression, abiraterone acetate dose was 
increased to 1gm twice daily, and patients were monitored for a minimum of 12 weeks or 
until subsequent PSA, radiographic, or clinical progression. 
4.2.4. Combining dutasteride with abiraterone acetate  
  This was a phase II, single-arm, multi-center, open-label study (NCT01393730) 
performed at Dana Farber Cancer Institute; all patients provided written informed consent. 
The main purpose of this research study was to determine the efficacy of adding dutasteride 
(SRD5A1 inhibitor) to abiraterone acetate and prednisone in patients with CRPC.  Our 
purpose was to determine whether adding dutasteride would alter abiraterone metabolism 
by blocking D4A metabolism to the 5α-reduced metabolites, which may increase the levels 
of D4A and abiraterone, thus may be correlated with the clinical outcomes. Patients were 
treated with abiraterone acetate (1gm daily) and prednisone (5 mg daily) for two 4-week 
cycles. After this time, high-dose dutasteride (3.5 mg daily) was added (start of cycle 3). 
Patients continued on the 3-drug regimen until study withdrawal or radiographic disease 
progression. Blood samples were available from beginning of cycle 3, cycle 4, and cycle 
7.    
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4.3. Results and Discussion  
4.3.1. CRPC patients receiving standard dose of abiraterone acetate  
  This study is still recruiting patients in an ongoing basis. The patients included in 
the analysis were diagnosed with prostate cancer between January, 1994 and May, 2014 
and began treatment with abiraterone acetate between December, 2011 and May, 2015. 
Samples from 34 patients were available for LC-MS analysis. All seven abiraterone 
metabolites were detected despite the treatment duration or time to blood draw (Table 11). 
Abiraterone as a percentage of the total metabolites was the greatest compared to all other 
metabolites, with a mean value of 43%. The lowest metabolite percentage was 3β-OH-5α-
Abi at only 0.69% of the total metabolites. D4A has been reported to be more potent than 
abiraterone in inhibiting AR regulated gene expression. D4A levels never exceeded that of 
abiraterone in patients; the ratio of D4A: abiraterone ranged from 0.03-0.36 with a mean 
of 0.07. On the other hand, the ratio of 3-keto-5α-Abi:D4A ranged from 0.84-12.94 with a 
mean of 3.73. PSA concentration and HSD3B1genotype (a gene that can be mutated in 
CRPC patients) were evaluated for any correlation with the metabolite levels. However, 
due to the limited number of patients with a mutated gene (n=3) it was difficult to find 
correlations between the metabolite levels with the genotype and clinical outcomes. 
4.3.2. Neoadjuvant study of abiraterone in combination with an LHRH agonist 
 Patients were enrolled from September 2009 through June 2011. Patients were 
randomized to treatment with abiraterone in combination with leuprolide and prednisone 
or leuprolide alone for 12 weeks. Then all patients received another 12 weeks of 
combination abiraterone, leuprolide and prednisone. After 24 weeks of neoadjuvant 
therapy, patients underwent surgery (prostatectomy). Abiraterone and leuprolide were able 
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to suppress tissue androgens more effectively compared to leuprolide alone. Samples from 
15 patients were available for LC-MS analysis. Abiraterone metabolites were detected in 
both tissue and serum. In general, abiraterone levels in serum were lower than in tissue 
when calculated as percentage of all metabolites (Fig 17A). SRD5A activity is high in the 
prostate; thus, the D4A percentage was higher in serum than in the prostate (Fig 17B). 
Among all 5-reduced metabolites (Fig 17C-H), 3β-OH-5α-abi has higher tissue levels. For 
no metabolite did the concentration correlate with androgen levels in tissue or serum. 
However, the percentage of 3α-OH-5β-Abi and 3β-OH-5β-Abi in tissue and abiraterone in 
serum were correlated with baseline serum PSA when calculated using the Kruskal-Wallis 
test (Table 12).  
4.3.3. Effect of increasing frequency to abiraterone acetate  
Forty-one patients enrolled in the study from March 2013 to March 2014. In 14 of 
the 41 patients, the abiraterone dose was increased to 1 gm twice daily. When compared 
with the standard abiraterone acetate dose, abiraterone levels increased in 10 patients (Fig 
18A), D4A levels increased in 8 (Fig 18B). Similar to abiraterone, 3-keto-5α-Abi levels 
increased in 10 patients (Fig 18C). 3α-OH-5α-Abi, 3β-OH-5α-Abi, and 3β-OH-5α-Abi had 
an increased levels in 9 patients (Fig 18D,E&G). 3-keto-5β-Abi and 3β-OH-5β-Abi 
increased in 12 of 14 patients (Fig. 18F&H). Overall, a non-significant increase in median 
abiraterone metabolite levels was observed in patients taking the increased dose, from 13.6 
ng/mL at the time of progression on the standard daily abiraterone dose to 16.2 ng/mL on 
the increased dose (Table 13). Despite the escalated abiraterone dose, none of the patients 
had a 30% decline in PSA at study end.    
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Table 11. Concentration ng/ml of abiraterone metabolites in CRPC patients  
Patient 
# 
Time 
point 
hour, min 
Abi D4A 
3- 
keto-
5α-
Abi 
3α-
OH-
5α-
Abi 
3β-
OH-
5α-
Abi 
3-
keto-
5β-
Abi 
3α-
OH-
5β-
Abi 
3β-
OH-
5β-
Abi 
1 1,20 15.75 0.96 6.99 1.77 0.58 7.08 10.19 22.54 
2 2,00 8.64 1.28 1.36 0.42 0.12 2.43 6.46 9.42 
3 2,00 89.88 2.52 10.84 2.07 2.12 21.97 32.81 41.56 
4 2,15 39.98 1.28 3.46 0.23 0.11 6.46 2.04 3.08 
5 2,15 40.49 2.05 9.07 1.30 0.39 4.37 4.90 5.71 
6 2,30 48.45 1.29 10.66 1.16 0.52 5.95 3.44 6.86 
7 3,15 2.19 0.29 0.58 0.22 0.08 0.91 3.15 1.50 
8 3,15 213.4 7.19 28.63 3.00 0.97 45.34 16.90 34.94 
9 4,16 9.28 3.30 2.84 0.61 0.14 20.22 21.29 33.20 
10 4,49 13.96 0.77 2.25 0.48 0.16 2.50 3.98 6.75 
11 4,50 81.90 4.11 6.73 1.13 0.40 21.74 22.28 19.10 
12 6,20 111.4 5.04 65.22 8.09 1.77 46.64 21.05 27.82 
13 6,40 43.41 3.67 20.48 5.87 4.14 12.74 22.04 19.06 
14 7,30 21.50 1.29 1.04 0.26 0.12 4.48 5.52 12.54 
15 8,08 61.47 4.54 9.88 1.73 0.60 14.77 11.85 24.32 
16 8,10 16.68 2.78 3.64 0.88 0.35 18.59 26.08 28.06 
17 8,11 16.71 1.25 8.10 1.93 0.45 8.08 9.84 15.19 
18 9,00 24.30 1.61 1.57 0.43 0.20 10.80 15.83 16.22 
19 9,20 10.75 0.44 0.87 0.24 0.10 0.64 2.02 2.41 
20 10,25 60.64 2.49 10.96 2.82 0.78 7.15 11.11 10.76 
21 10,40 35.88 1.82 12.46 3.69 0.99 5.98 10.52 16.37 
22 10,45 19.24 0.52 1.22 0.37 0.15 1.28 3.83 4.33 
23 11,15 68.76 5.35 15.04 3.27 1.14 17.17 18.59 24.81 
24 11,40 49.87 4.00 11.74 2.22 0.93 15.29 11.25 21.34 
25 11,50 33.53 2.08 4.57 1.08 0.32 3.77 4.13 4.32 
26 11,50 67.98 3.59 5.36 1.11 0.44 16.54 12.53 27.29 
27 12,10 41.22 3.71 11.04 2.27 0.77 25.76 21.59 37.91 
28 12,15 19.06 1.14 4.66 1.21 0.34 11.54 10.95 12.50 
29 12,15 52.41 3.17 10.89 2.83 0.88 8.97 10.57 19.10 
30 12,20 38.32 2.16 7.59 1.26 0.51 9.12 6.13 10.10 
31 13,20 46.60 2.33 15.07 2.95 1.02 23.00 16.96 31.13 
32 13,05 22.59 2.41 4.43 0.72 0.27 5.79 5.47 6.16 
33 14,08 31.48 3.07 20.28 6.42 1.99 7.89 19.94 15.87 
34 15,45 66.69 2.83 8.71 2.88 0.88 4.29 10.53 12.34 
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Table 12. Correlation between tissue and serum metabolites with baseline PSA 
Analyte 
Tissue vs  
Baseline Serum 
PSA 
Serum  vs  
Baseline Serum 
PSA 
Coef P Coef P 
Abiraterone -0.56* 0.03 -0.56 0.03 
D4A 0.41 0.13 0.41 0.13 
3-keto-5α-Abi 0.43 0.11 -0.01 0.96 
3α-OH-5α-Abi 0.28 0.31 -0.09 0.74 
3β-OH-5α-Abi 0.16 0.57 -0.05 0.87 
3-keto-5β-Abi 0.41 0.13 -0.03 0.92 
3α-OH-5β-Abi 0.54 0.038 -0.09 0.75 
3β-OH-5β-Abi 0.53 0.043 0.09 0.75 
 *A negative coefficient indicates the values between metabolites and PSA were inversely correlated 
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Figure 17. Abiraterone metabolites in human prostate and serum. A, Abi; B, D4A; C, 3-
keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-keto-5β-Abi; G, 3α-OH-5β-Abi; 
and H, 3β-OH-5β-Abi. 
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Figure 18. Metabolite concentration (ng/ml) after 1gm once vs. twice daily of abiraterone 
acetate. A, Abi; B, D4A; C, 3-keto-5α-Abi; D, 3α-OH-5α-Abi; E, 3β-OH-5α-Abi; F, 3-
keto-5β-Abi; G, 3α-OH-5β-Abi; and H, 3β-OH-5β-Abi. 
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Table 13. Abiraterone dose dependent concentrations 
Analyte 1gm/daily 1gm twice/daily P 
Abiraterone 13.57 16.21 0.25 
D4A 1.36 1.53 0.24 
3-keto-5α-Abi 4.69 6.45 0.29 
3α-OH-5α-Abi 1.04 1.33 0.37 
3β-OH-5α-Abi 0.36 0.42 0.76 
3-keto-5β-Abi 3.55 6.62 0.12 
3α-OH-5β-Abi 7.19 9.05 0.25 
3β-OH-5β-Abi 15.14 18.12 0.21 
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4.3.4. Effect of adding dutasteride 
  Based on the analysis of the clinical trial with standard abiraterone acetate dose, 
(section 4.3.1.) 3-keto-5α-Abi:D4A ratio was 3.73. To test whether adding a SRD5A 
inhibitor will lower this ratio, samples from the clinical trial (NCT01393730) were 
analyzed. Patients enrolled between September 2011 and October 2012. Sixteen patients 
who had blood collected on abiraterone acetate alone (start of cycle 3) and after the addition 
of dutasteride (start of cycles 4 and 7) were included in the analysis (Fig 19A). Adding 
dutasteride doubled the mean concentrations of abiraterone and D4A (191.2 nM vs.372.4 
nM and 9.9 nM vs. 18.2 nM ; respectively (Table 14 and Fig 19B&C).  
  On the other hand, adding dutasteride resulted in a dramatic decline in the 5α-
reduced metabolites: 89% decline in the mean concentration of 3-keto-5α-Abi, 92% for 3α-
OH-5α-Abi, and 73% for 3β-OH-5α-Abi (Table 14 and Fig. 19D).  Concentrations of 
abiraterone, D4A, and 5α-Abi metabolites at cycle 7, the second time point after addition 
of dutasteride, were similar to cycle 4 (Table 14).  Finally, the addition of dutasteride, did 
not decrease any of the 3 5β-reduced abiraterone metabolites, supporting a very specific 
biochemical effect of SRD5A inhibition on 5α-Abi metabolism (Fig 19E). The significance 
of adding dutasteride was evaluated between cycle 3 and 4 using a paired two-tailed t-test 
(Table 14).   Together, these findings demonstrate that the elevated ratio of 5α-Abi:D4A 
in standard therapy can be lowered with dutasteride. 
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Figure 19. Effect of adding dutasteride to abiraterone; clinical trial (NCT01393730). A, 
Study design; B, Abi; C, D4A; D, 5α-reduced metabolites; E, 5β-reduced metabolites. 
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Table 14. Effect of dutasteride on abiraterone metabolites concentrations (nM) 
Analyte Cycle 3 
Cycle 
4 
Cycle 
4 P 
Abiraterone 191.20 372.40 305.40 0.051 
D4A 9.94 18.18 17.85 0.002 
3-keto-5α-Abi 25.76 2.94 4.42 <0.0001 
3α-OH-5α-Abi 6.09 0.50 0.80 <0.0001 
3β-OH-5α-Abi 2.69 0.73 1.25 <0.0001 
3-keto-5β-Abi 38.74 49.94 60.29 0.11 
3α-OH-5β-Abi 47.78 48.00 56.59 0.97 
3β-OH-5β-Abi 74.05 69.51 91.43 0.64 
 P value Cycle 3 vs Cycle 4 
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4.4. Conclusion  
Abiraterone was approved in 2012 based on the outcome of the clinical trial where 
it showed an increase in overall survival.  Since then, improving the drug is an ongoing 
aim for many researchers. Although the clinical trials described in this chapter were not 
designed to study abiraterone metabolites, we were able to detect abiraterone metabolites 
in order to determine whether the levels of the metabolites can be used as a potential 
biomarker and be correlated with clinical outcomes. None of the studies gave a clear 
correlation between the metabolite levels and the clinical outcomes but this is something 
that researchers need to take into consideration in future designs. In the abiraterone plus 
LHRH agonist leuprolide (neoadjuvant) study, the 5α-reduced metabolites were present in 
serum and the tissue at higher levels than D4A.  The increased dose of abiraterone did 
lower PSA but it did not achieve the study goal of a 50% decline, and although the 
increased dose also raised the D4A level, the ratio D4A:3-Keto-5α-Abi remained the same. 
However, combining abiraterone acetate with dutasteride can reverse the ratio by leading 
to higher D4A.  
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CHAPTER V 
BIOCHEMICAL ACTIVITIES OF GALETERONE STEROIDAL 
METABOLITES 
 
 
5.1. Introduction 
In an effort to overcome drug resistance in prostate cancer, several approaches were 
taken into consideration when designing new agents, specifically, targeting androgen 
biosynthesis by inhibiting steroidogenic enzymes or direct targeting and antagonizing the 
AR. Abiraterone and enzalutamide are FDA-approved for treatment of CRPC. Abiraterone 
inhibits the enzyme 17α-hydroxylase/17,20-lyase (CYP17A1) 1,2, whereas enzalutamide 
directly antagonizes the AR3,4.  Unfortunately, tumor resistance eventually develops against 
both of these agents and some evidence suggests that resistance to abiraterone is yet again 
engendered by a reinstatement of AR signaling5,6  
Currently under clinical development, galeterone (Gal), 17-(1H-benzimidazol-1-
yl) androsta-5,16-dien-3β-ol, is a steroidal 17-azole compound that inhibits CYP17A1, 
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directly competes with androgens to bind and antagonize AR, promotes AR protein 
degradation, and had clinical activity in a phase I/II clinical trial7-11.  Galeterone shares its 
Δ5, 3β-hydroxyl structure with abiraterone.  The two drugs are distinguished by their C17 
moieties – the benzamidazole ring of galeterone – and the 3-pyridyl structure of 
abiraterone.  These differences may explain why galeterone has been reported to have more 
direct effects on AR 
However, abiraterone is metabolized in vivo to Δ4-abiraterone (D4A), which more 
potently than abiraterone inhibits the androgen axis12, and 5α-abiraterone, which in contrast 
is an AR agonist that promotes tumor progression13. The differing activities of abiraterone 
and galeterone may be due to their respective steroidal metabolites that interact with 
steroidogenic enzymes and AR, which in turn may thus far have led to an incomplete 
accounting of the context and activities of the parent drugs.  However, metabolites of 
galeterone along steroidogenic pathways have not yet been identified (Fig. 20).   
The aim of this chapter is to describe in vitro and in vivo galeterone metabolism by 
steroidogenic enzymes and to evaluate galeterone metabolite activity in prostate cancer.    
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Figure 20. Steroidogenic metabolism of galeterone 
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5.2. Experimental Section 
5.2.1. Cell lines and chemicals 
LNCaP, 293T and VCaP cells were purchased from the American Type Culture 
Collection (Manassas, VA) and maintained in RPMI-1640 (LNCaP) or DMEM (293T and 
VCaP) with 10% FBS. LAPC4 cells were kindly provided by Dr. Charles Sawyers 
(Memorial Sloan Kettering Cancer Center, New York, NY) and grown in Iscove’s Modified 
Dulbecco’s Medium with 10% FBS. All experiments with LNCaP and VCaP cells were 
done in plates coated with poly-DL-ornithine (Sigma-Aldrich, St. Louis, MO).  A 293T cell 
line stably expressing human CYP17A1 was generated by transfection with plasmid 
pcDNA3-c17 (a generous gift of Dr. Walter Miller, University of California, San Francisco) 
and selection with G418 as described14.  Cell lines were authenticated by DDC Medical 
(Fairfield, OH) and determined to be mycoplasma-free using the following primers: 
5’-ACACCATGGGAGCTGGTAAT-3’   and  
5’-GTTCATCGACTTTCAGACCCAAGGCAT3’.  
Dutasteride was purchased from Medkoo Biosciences (Chapel Hill, NC). Methanol, 
acetonitrile, water, and formic acid were LC–MS grade and all were from Fisher Scientific 
(Fair Lawn, NJ). Double charcoal-stripped human serum was from Golden West Biological 
Inc. (Temecula, CA). Galeterone and D4G were purchased from Shanghai Forever 
Synthesis Co., Ltd. (Shanghai, China). 3-keto-5α-galeterone, 3α-OH-5α-galeterone, 3β-
OH-5α-galeterone, 3-keto-5β-galeterone, 3α-OH-5β-galeterone, and 3β-OH-5β-galeterone 
were synthesized in the laboratory of Dr. Richard Auchus, University of Michigan Medical 
School.  
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5.2.2. Cell line metabolism 
To test the hypothesis that galeterone would be metabolized by steroidogenic 
enzymes to D4G, and 6 metabolites downstream of D4G, two prostate cancer cell lines, 
LNCaP (which expresses mutant 3βHSD1 with high enzyme activity) 15 and LAPC4 
(which expresses wild-type 3βHSD1 with low enzyme activity) 15, were used. Cells were 
seeded and incubated in 12-well plates with 0.2 million cells/well for ~24 h and then 
incubated with 0.1µM of either galeterone, D4G or 3-keto-5α-Gal (5αG) for 24 and 48 hr. 
Media were collected at the two time points and were subjected to LC-MS analysis. This 
experiments was performed in triplicate for each drug and was repeated in three biological 
repeats. 
To confirm that steroidogenic enzymes directly metabolize galeterone, 3βHSD1, 
SRD5A1, or AKR1C2 was overexpressed in HEK-293 cells, which were then treated with 
galeterone, D4G, or 5αG respectively. Media were collected 3 and 6 hours after the 
treatment and were subject to LC-MS analysis.  
To study the effect of blocking SRD5A1 on D4G metabolism, LAPC4 cells (which 
express SRD5A1) were incubated with D4G with and without SRD5A1 inhibitors 
(dutasteride and LY191704) or short hairpin RNAs targeting SRD5A1. Media samples 
were collected 3 and 6 hours and were subjected to LC-MS analysis.    
5.2.3. In vivo metabolism 
To study the metabolism of galeterone in vivo, male NSG mice, 6 to 8 weeks of age 
were obtained from the Cleveland Clinic Biological Resources Unit. All mouse studies 
were conducted under a protocol approved by the Cleveland Clinic Institutional Animal 
Care and Use Committee. Mice (n = 3 mice/group) were injected intraperitoneally with 
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100 µL solution containing 0.15 mmol/kg of either galeterone, D4G, 3-keto-5α-Gal 3α-
OH-5α-Gal, or 3β-OH-5α-Gal. Blood was collected 2 and 4 hrs after injection, centrifuged 
at 10,000 rpm, and the sera were stored at -80ºC for LC-MS analysis. 
5.2.4. Effects of galeterone metabolites on steroidogenic enzyme activity 
To study the effect of galeterone metabolites on steroidogenic enzymes, three cell 
lines were used: HEK-293, LNCaP, and LAPC4. HEK-293 cells overexpressing CYP17A1 
were treated with [3H]-pregnenolone in the presence of D4A (0.1, 1 and 10 nM), or 
galeterone and its metabolites (1, 10 and 100 nM), for 3 and 6 h, and conversion to DHEA 
was assessed by HPLC.  LNCaP cells were treated with [3H]-DHEA and the indicated 
drugs at 0.1, 1.0, and 10 μM for 24 and 48 h, and the conversion to AD was assessed by 
HPLC. LAPC4 cells were treated with [3H]-AD and 1, 5 and 10 µM of the indicated drugs 
for 8 and 24 h, and flux to 5α-dione was assessed by HPLC. All experiments went through 
the same protocol as follows: 12-well plates with 0.2 million cells/well for ~24 h and then 
incubated with indicated drugs or a mixture of radioactive ([3H]-labeled) and non-
radioactive steroids (final concentration, 100 nM; ~1,000,000 cpm/well; PerkinElmer, 
Waltham, MA) at 37ºC.  Aliquots of medium were collected at the indicated times.  
5.2.5. AR competition assay 
The affinity of galeterone and its metabolites for mutated or wild-type AR were 
assessed as follows: LNCaP (mutated AR) or LAPC4 (wild-type AR) were cultured in 
serum-free medium for 48 h and then incubated with [3H]-R1881 with or without the drugs 
(D4A, galeterone, D4G, 5α-Gal) for 30 min. Cells were washed with 1X PBS 4 times and 
0.9% NaCl solution twice before lysis with RIPA buffer. Intracellular radioactivity was 
measured with a Beckman Coulter LS60001C liquid scintillation counter and normalized 
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to the protein concentration as detected with a Wallac Victor2 1420 Multilabel counter 
(Perkin Elmer). 
5.2.6. Effects of galeterone metabolite on AR-regulated gene expression  
To study the effect of galeterone metabolites on AR target gene expression. LNCaP 
and LAPC4 cells were serum starved for 48 h before treatment with DHT (0.5 or 0.1 nM, 
respectively) and 1 μM of galeterone, D4G, 5α-Gal, D4A or 5α-Abi for 24 h.  Cells were 
starved with phenol red-free and serum-free medium. RNA was extracted with a GenElute 
Mammalian Total RNA miniprep kit (Sigma-Aldrich). cDNA was synthesized from 1 µg 
RNA in a reverse transcription reaction using the iScript cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA). Quantitative PCR (qPCR) analysis was conducted in triplicate with primers 
for PSA, TMPRSS2, and RPLPO (housekeeping gene) in an ABI 7500 Real-Time PCR 
machine (Applied Biosystems) using iTaq Fast SYBR Green Supermix with ROX (Bio-
Rad) in 96-well plates at a final reaction volume of 20 µL. Accurate quantitation of each 
mRNA was achieved by normalizing the sample values to RPLPO and to vehicle-treated 
cells. 
5.2.7. Mouse xenograft studies 
All mouse studies were conducted under a protocol approved by the Cleveland 
Clinic Institutional Animal Care and Use Committee. Male NSG mice, 6 to 8 weeks of age 
were obtained from the Cleveland Clinic Biological Resources Unit.  
In order to study the efficacy of D4G as a tumor suppresser, D4G was compared 
with galeterone. 107 VCaP cells were injected subcutaneously with Matrigel into surgically 
orchiectomized NSG mice that were implanted with 5 mg 90-day sustained-release DHEA 
pellets (Innovative Research of American, Sarasota, FL) to mimic human physiology. Once 
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tumors reached 300 mm3 (length × width × width × 0.52), the mice were arbitrarily 
assigned to vehicle (n=11), galeterone (n=11), or D4G (n=11) treatment groups. Galeterone 
and D4G (0.15 mmol/kg in 0.10 mL 15% ethyl alcohol in safflower oil) were administered 
via 5 mL/kg intraperitoneal injection twice daily, 5 days per week for up to 20 days. Control 
groups were administered 0.10 mL of a solution of 15% ethyl alcohol in safflower oil. Once 
the treatment was started, tumor volume was measured with calipers three times per week, 
and time to increase in tumor volume by 20% was determined. Mice were sacrificed at 
treatment day 20.  The significance of the difference between treatment groups was 
assessed by Kaplan-Meier survival analysis using a log-rank test in SigmaStat 3.5.  
Student’s t-test was used to determine significance between different treatments. 
To evaluate whether 3-keto-5α-Gal enhances tumor growth, it was compared with 
3-keto-5α-Abi which has been shown previously to enhance tumor growth in mice13. 107 
VCaP cells were injected subcutaneously with matrigel. Once tumors reached 100 mm3 
(length × width × width height × 0.52), mice were surgically orchiectomized and arbitrarily 
assigned to vehicle (n=9), 3keto-5α-Abi (n=9), or 3keto-5α-Gal (n=9) treatment groups. 
3keto-5α-Abi and 3keto-5α-Gal (0.15 mmol/kg in 0.10 mL 15% ethyl alcohol in safflower 
oil) were administered via 7.55 mL/kg intraperitoneal injection once daily, 5 days per week 
for 24 days. Control groups were administered 0.1 mL of a solution of 15% ethyl alcohol 
in safflower oil. Tumor volume was measured every other day, and time to increase in 
tumor volume by 30% was determined. Mice were sacrificed at treatment day 24.  The 
significance of the difference between treatment groups was assessed by Kaplan-Meier 
survival analysis using a log-rank test in SigmaStat 3.5.  Student’s t-test was used to 
determine significance.   
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5.2.8. High-performance liquid chromatography (HPLC) 
Collected medium from the experiments in section 5.2.4. was treated with 1,000 
units of β-glucuronidase (Helix pomatia; Sigma-Aldrich) at 37°C for 2 h, extracted with 
860 µL ethyl acetate:isooctane (1:1), and concentrated under nitrogen gas. HPLC analysis 
was performed on a Waters 717 Plus HPLC or an Agilent 1260 HPLC.  Dried samples were 
reconstituted in 100 µl 50% methanol and injected into the instrument. Steroids were 
separated on a Kinetex 100 × 2.1 mm, 2.6 µm particle size C18 reverse-phase column 
(Phenomenex, Torrance, CA) using a methanol/water gradient at 30°C. The column 
effluent was analyzed using a dual-wavelength UV-visible detector set at 254 nm or β-
RAM model 3 in-line radioactivity detector (IN/US Systems, Inc.) and Liquiscint 
scintillation cocktail (National Diagnostics, Atlanta, GA). All HPLC studies were 
conducted in triplicate and repeated at least 3 times in independent experiments. 
5.2.9. Mass spectrometry 
Galeterone and its seven steroidal metabolites were determined using the validated 
LC-MS method for the determination of abiraterone and its seven structurally related 
metabolites16 with slight modifications. The mobile phase consisted of 30% A (0.2% formic 
acid in water) and 70% B (0.2% formic acid in methanol:acetonitrile, 60:40).  Separation 
of the metabolites was achieved using a Zorbax Eclipse plus 150 x 2.1 mm, 3.5µm C18 
column (Agilent, Santa Clara, CA) at a flow rate of 0.2 ml/min. Drug metabolites were 
ionized using electrospray ionization in positive ion mode.  
The LC-MS method was applied to analyze cell media and mouse serum samples. 
To 200 µL media, 40 µL internal standard (abiraterone) was added, then the analytes were 
extracted with 2 ml TMBE (Sigma Aldrich, St. Louis, MO), the TMBE was evaporated, 
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and the sample reconstituted with 200 µL (methanol:H2O; 1:1). The standard curves were 
prepared in media. The metabolites were extracted from 20 µl mouse serum by adding 280 
µl methanol containing the internal standard. The samples were then vortexed and 
centrifuged at 12,000 rpm for 10 min, and 200 µl supernatant was transferred to the HPLC 
vial.  
To extract the metabolites from the tumor, tumor (28.3-63.3 mg) was homogenized 
with 750 µl LC-MS grade water.  Then 75 µl internal standard (abiraterone) was added to 
the mixture, the metabolites were extracted from the homogenate using 2.5 ml TMBE, the 
organic layer was then evaporated, and the samples were reconstituted with 300 µl 
methanol: water (50:50). 
5.3. Results and Discussion 
5.3.1. Galeterone metabolite separation by LC-MS/MS  
The modifications of abiraterone validated LC-MS/MS method resolved all 
galeterone metabolites (Fig 21). The method was applied to detect galeterone metabolites 
in cell media, mouse serum, and mouse tumor  
5.3.2. In vitro metabolism of galeterone by steroidogenic enzymes 
After treating LNCaP and LAPC4 cells with galeterone for 24 or 48h, galeterone 
metabolites including D4G, 5αG, 3α-OH-5αG and 3β-OH-5αG were detected by LC-MS. 
Metabolism of galeterone to D4G and to subsequent 5α-reduced metabolites was more 
robust in LNCaP than LAPC4 cells (Fig. 22A&B), consistent with the known high 3βHSD 
enzyme activity in LNCaP cells. D4G was converted to 5αG, 3α-OH-5αG, and 3β-OH-
5αG but not back to galeterone, indicating that conversion from galeterone to D4G is 
irreversible. 5αG treatment led to the production of 3α-OH-5αG and 3β-OH-5αG but not 
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D4G or galeterone.  No 5β-reduced metabolites were detectable, consistent with the 
absence of 5β-reductase activity in prostate cancer cell lines.  
Expression of 3βHSD1 in HEK-293 cells permitted the conversion from galeterone 
to D4G (Fig. 23A). Similarly, expression of SRD5A1 or SRD5A2 resulted in the 
conversion of D4G to 5αG (Fig. 23B). Expression of AKR1C2, the major enzyme that 
converts endogenous 3-keto steroids such as DHT to their 3α-OH metabolites, enabled the 
conversion from 5αG to 3α-OH-5α-Gal in a time- and concentration-dependent manner 
(Fig. 23C). In LAPC4 cells with endogenous SRD5A1 activity, the SRD5A inhibitor 
LY191704 or dutasteride blocked the conversion from D4G to 5αG (Fig. 24A). Stable 
SRD5A1 knockdown with short hairpin RNAs similarly ablated metabolism from D4G to 
5αG (Fig. 24B). Together, these data support the hypothesis that galeterone undergoes 
direct metabolism by steroidogenic enzymes, similar to endogenous steroids and the 
structurally related drug, abiraterone. 
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Figure 21. LC-MS separation of all galeterone metabolites. The results were obtained by 
injecting 10 μL of 50 ng/mL standard mixture of galeterone and its metabolites. 
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Figure 22. Metabolism of galeterone and its metabolites in A, LNCAP and B, LAPC4 
cells 
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Figure 23. Steroidogenic enzymes required for galeterone metabolism. Overexpressing 
of A, 3βHSD1; B, SRD5A; and C, AKR1C2 resulted in converting the precursors.   
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Figure 24. Effect of blocking SRD5A1 on D4G metabolism. D4G conversion was 
blocked A, Pharmacologically or B, genetically.    
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5.3.3. In vivo metabolism  
Galeterone and its metabolites were injected into NSG mice to determine its 
metabolism in vivo (Fig. 25). In addition to D4G and the three 5α-reduced metabolites, 
three 5β-reduced metabolites – 5βG, 3α-OH-5βG and 3β-OH-5βG – were detected in 
mouse serum after galeterone injection. Furthermore, injecting any one 5αG-compound led 
to detection of all three 5α-reduced metabolites, which indicates that 5αG, 3α-OH-5α-G 
and 3β-OH-5α-G are interconvertible in vivo. In subsequent studies, we focused on D4G 
and the 5α-reduced metabolites because 5α-reduction leads to the formation of a planar 
structure, as occurs with the most potent endogenous androgen, DHT17,18. On the other 
hand, 5β-reduction of 3-keto steroids introduces a 90° bend, which generally inactivates 
steroid hormones and facilitates their clearance. 
5.3.4. Effects of galeterone metabolites on steroidogenic enzyme activity 
Galeterone was reported to be more potent than abiraterone against CYP17A1 
expressed in E. coli7,19. However, the comparative effects of their respective metabolites 
on steroidogenic enzymes is not known. D4A, the abiraterone metabolite that most potently 
inhibits steroidogenesis, was compared with galeterone and its metabolites12. In HEK-293 
cells stably expressing CYP17A1, D4A, at a concentration of 10 nM, completely blocked 
CYP17A1-catalyzed conversion of [3H]-pregnenolone to DHEA. Galeterone and its 
metabolites were approximately 100-fold weaker in blocking the production of DHEA 
(Fig. 26A). This result indicated that galeterone and its metabolites are 100-fold less potent 
than D4A in blocking CYP17A1 activity. In LNCaP cells, which possess high 3βHSD 
enzyme activity, galeterone inhibited the conversion of [3H]-DHEA to Δ4-androstenedione 
(AD), comparably to D4G and D4A (Fig. 26B). Conversion from D4G to 5αG slightly 
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reduces the capacity to inhibit 3βHSD1 activity. D4G was more potent than galeterone and 
comparable to D4A in inhibiting SRD5A activity, as assessed with the conversion of [3H]-
AD to 5α-dione in LAPC4 cells (Fig. 26C).  
5.3.5. The effect of galeterone and its metabolites on AR and AR signaling 
Galeterone has been reported to directly bind to and enhance the degradation of 
AR10. To determine the affinity of galeterone and its metabolites for AR, a competition 
assay was performed. The affinity of D4G for mutant AR (expressed in LNCaP, T877A) 
and wild-type AR (expressed in LAPC4 cells) was greater than that of galeterone, 
comparable to that of D4A, and comparable to or slightly greater than that of 5αG (Fig. 
27A&B). To assess the functional consequences of galeterone and its metabolites, their 
effects on expression of androgen-responsive genes were investigated. Galeterone and 
D4G inhibited DHT-induced AR-target gene expression in LNCaP and LAPC4 cells, 
comparable to D4A (Fig. 27C&D). To a lesser extent, 5αG also suppressed DHT-induced 
gene expression. Notably, however, 5αG somewhat increased basal PSA expression in the 
absence of DHT in LNCaP cells. Compared with 3-keto-5α-abiraterone (5α-Abi), a weak 
AR agonist, 5αG is an even weaker agonist (Fig. 27C&D). Taken together, these data 
indicate that the conversion from galeterone and D4G by SRD5A to 5αG may lead to a 
diminished effect on AR stability and AR-responsive gene expression. 
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Figure 25. Galeterone metabolism in vivo. A, Galeterone; B, D4G; C, 3-keto-5α-Gal; D, 
3α-OH-5α-Gal; E, 3β-OH-5α-Gal. 
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Figure 26. Effect of galeterone metabolites on steroidogenic enzyme activity. A, effect on 
CYP17A; B, 3βHSD1; and C, SRD5A1 
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Figure 27. Effect of galeterone metabolites on AR signaling. Affinity of the metabolites 
to AR in A, LNCAP and B, LAPC4 cells. The effect of the metabolites on AR regulated 
gene expression in C, LNCAP and D, LAPC4 cells. 
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5.3.6. Galeterone metabolite effects on tumor progression in a mouse xenograft 
model   
The effect of D4G on tumor growth in a xenograft mouse model was studied 
because D4G was comparable to or slightly better than galeterone in blocking 
steroidogenesis and suppressing AR regulated gene expression. VCaP xenografts were 
grown subcutaneously in orchiectomized mice with DHEA pellet implantation to mimic 
human adrenal androgen physiology. Time from initiation of treatment with D4G, 
galeterone, or vehicle to tumor progression (>20% increase in tumor volume) was assessed 
by generating Kaplan–Meier survival curves, and comparing treatment groups with the log-
rank test. Galeterone inhibited xenograft growth (vehicle vs. galeterone, p=0.01). 
Xenograft progression was also significantly delayed in the D4G group compared with the 
vehicle group (p=0.02) and was no different when compared to the galeterone group (D4G 
vs galeterone, p=0.98) (Fig. 28). LC-MS analysis for galeterone and its metabolites in 
serum and tumors collected at the study end confirmed that conversion to downstream 
galeterone steroidal metabolites is detectable in both xenografts and serum (Fig. 29A&B). 
Due to 3-keto-5α-Gal ability to stimulate AR regulated gene expression, the effect 
of 3-keto-5α-Gal activity on xenograft tumor progression was studied in orchiectomized 
mice injected subcutaneously with VCaP xenografts. The mice were assigned to vehicle, 
3-keto-5α-Gal, or 5α-Abi. Time from initiation of treatment to tumor progression (>30% 
increase in tumor volume) was assessed by generating Kaplan–Meier survival curves and 
comparing treatment groups with the log-rank test (Fig 30). Tumors from vehicle-treated 
mice did not differ from those receiving 3-keto-5α-Gal (P=0.125), nor did tumors from 
mice receiving 3-keto-5α-Gal treatment differ from those receiving 5α-Abi (P=0.20).  
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Figure 28. Survival curve of mice treated with galeterone or D4G. Galeterone and 
D4G will delay the growth of mouse xenograft compared to vehicle.  
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Figure 29. Metabolite percentages in tumor and serum. The results were obtained from 
LC-MS analysis for A, tumor samples and B, serum samples.  
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Figure 30. Effect of 5α-galeterone on tumor growth. 5α-Abi and 5α-Gal promote tumor 
progression in mouse xenograft.  
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5.4. Conclusions 
Galeterone undergoes steroidogenic metabolism to generate D4G, 3-keto-5α-Gal, 
3-keto-5β-Gal and 4 other steroidal metabolites. This pathway was confirmed both in vitro 
and in vivo. Galeterone metabolites had opposing effects on prostate tumors in the 
xenograft models. Whereas D4G inhibits steroidogenic enzymes, AR-regulated gene 
expression, and tumor progression, its conversion resulted in loss of activity and generation 
of 3-keto-5α-Gal, which promoted AR target gene expression and enhanced tumor growth. 
Galeterone follows the same steroidogenic metabolism as abiraterone, which suggests a 
novel pathway for metabolism of steroidal 3β-OH Δ5 analogues, which should be 
considered in future drug design.   
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CHAPTER VI 
PROJECT CONCLUSIONS AND FUTURE DIRECTIONS 
 
CYP17A1 is a clinically validated target for the treatment of CRPC1-3. Non-
steroidal and steroidal CYP17A1 inhibitors are both undergoing pharmacologic and 
clinical development; however, the consequences of using steroidal vs. non-steroidal drugs 
are not well understood. Here, I determined that abiraterone and galaterone, Δ5, 3β-
hydroxyl steroidal drugs, are converted to at least seven steroidal metabolites that are either 
3-keto Δ4, (1 metabolite) 5α-reduced (3 metabolites), or 5β -reduced (3 metabolites) in vitro 
and in vivo, and have important downstream consequences on the androgen axis. Therefore, 
steroidogenic metabolism of drugs with the Δ5, 3β-hydroxyl structure appears to be a class 
effect, instead of being a property that is unique to a single drug.  The activity of these 
metabolites is a critical issue with broad consequences for drug development across 
steroid-dependent diseases. 
The development of the LC-MS/MS method that distinguished the metabolites gave 
a clear picture and understanding of abiraterone and galeterone metabolism. Despite its 
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novelty in separating all the diasteroisomers, the method did not require any sophisticated 
techniques and was developed using materials that are available in any analytical lab.    
An important property that distinguishes galeterone from abiraterone is that 
galeterone has been reported to have direct properties as an AR antagonist and degrader, 
while CYP17A1 is generally thought to be the main direct target of abiraterone.  However, 
conversion of galeterone by 3βHSD and SRD5A to other metabolites that are formed in 
vitro and in vivo, with varying biochemical activities, clearly has consequences on 
steroidogenic enzymes and direct effects on AR.  Importantly, D4G and 5αG bind AR more 
potently than galeterone, although both of these metabolites downstream of 3βHSD have 
divergent effects on AR.  Interestingly, despite the increased affinity for AR and 
maintaining AR enhanced degradation activity, the activity of D4G in a xenograft model 
of CRPC was no better than that of galeterone.  It is possible that any increased anti-tumor 
xenograft activity by D4G was reversed because it is one metabolic step closer to 5αG, 
resulting in higher intratumoral concentrations of the latter. This result raises the possibility 
that SRD5A inhibition to block 5αG synthesis might be beneficial. 
These findings also suggest that the design and use of steroid-based drugs for 
prostate cancer should consider the relative activities of steroidogenic enzymes in prostate 
cancer.  For example, abiraterone and galeterone are rapidly converted to their steroidal 
metabolites in cells that have high, but not low, 3βHSD1 activity.  A published head-to-
head comparison of galeterone vs. abiraterone in LAPC4 xenografts demonstrated 
galeterone to have superior activity4.  However, 3βHSD1 activity is low in LAPC4 cells, 
and therefore this comparison likely was more selectively focused on galeterone and 
abiraterone.  The consequences of downstream galeterone metabolites are more likely to 
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be seen in cancer models and patients that have the 3βHSD1 N367T missense that 
accumulates and results in high activity5. 
The presence of steroidal abiraterone metabolites in patients was confirmed by 
analyzing samples from patients who underwent treatment with abiraterone acetate6,7. The 
metabolite levels can be altered by combining abiraterone acetate with other drugs like 
SRD5A inhibitors which may maximize the benefits of the treatments. Although increasing 
the standard dose of abiraterone acetate resulted in increasing D4A levels, it also increased 
5α-Abi and therefore maintained the percentage of both the good and the bad metabolites.   
In prostate tissue, which expressed high SRD5A1activity, the D4A level was lower than 
the 5α-Abi level. All these results indicate that new strategies are critically needed in 
treatment options that involve abiraterone acetate. 
Galeterone is under study in clinical trials; therefore, this work was limited by 
patient sample availability; as a result it was not possible to assess the metabolites in 
clinical samples.  However, given the similar metabolic behavior of galeterone and 
abiraterone in prostate cancer models, in vivo and with specific steroidogenic enzymes, it 
is highly likely that the concentrations of galeterone metabolites are significant and similar 
to abiraterone metabolites in patients.   
In summary, our results provide a more complete picture of abiraterone and 
galeterone metabolism and activity.  These findings demonstrate that metabolism by 
steroidogenic enzymes is a class effect of Δ5, 3β-hydroxyl drugs that should be accounted 
for in preclinical and clinical drug development and distinguishes these agents from non-
steroidal inhibitors.  The levels of these metabolites and their respective activities are 
determined by the expression and activity of endogenous steroidogenic enzymes, including 
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3βHSD and SRD5A. These findings must be considered for the development of better 
treatment strategies. 
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